Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    1 CONFIDENTIAL  RZL -012 Study Protocol  
Protocol Number  RZL -012-FD-P2aUS -001.7 
 
An open label, phase 2a clinical trial for the evaluation of safety and efficacy of RZL -012 
for the treatment of women with lipedema involving substantial fat above the knee or of 
women and men with nodular Dercum's disease.  
  Principal Investigator:  
Karen  Herbst  
Sponsor:  
Raziel Therapeutics LTD  
Hadassah Ein -Karem, JBP building, P.O.B. 12157  
Jerusalem, Israel 9112101  
Confidentiality Statement  
This document is a confidential communication of Raziel Therapeutics Ltd. 
Acceptance of this document constitutes agreement by the recipient that no 
unpublished information contained herein will be published or disclosed without 
prior written approval, except for  disclosure to the appropriate Institutional 
Review Board and/or Regulatory Authority under the condition that confidentiality 
is maintained  
Protocol Date:  4 June  2017  
Version 1:  4 June  2017  
Version 2: 11 November  2017  
Version 3: 26 January  2018  
Version 4: 8 March  2018  
Version 5: 12 July 2018  
Version 6: 23 July 2018  
Version 7: 03 Jan 2019  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    2 CONFIDENTIAL   
 
 
 
TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................ ................................ ................................ ................. 2 
LIST OF TABLES  ................................ ................................ ................................ ........................... 7 
LIST OF FIGURES  ................................ ................................ ................................ ......................... 7 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ .......... 8 
STATEMENT OF COMPLIANCE  ................................ ................................ ............................... 11 
INVESTIGATOR SIGNATURE PAGE  ................................ ................................ ....................... 12 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ .............. 13 
1. INTRODUCTION  ................................ ................................ ................................ ......21 
1.1. BACKGROUND  ................................ ................................ ................................ ........ 21 
1.1.1.  Scien tific Background and Clinical Rationale  ................................ ............................ 21 
1.1.2.  RZL -012 Formulation Development  ................................ ................................ .......... 23 
1.2. NONCLINICAL ASSESSMENTS  ................................ ................................ ............ 24 
1.2.1.  Pharmacology  ................................ ................................ ................................ ............. 24 
1.2.1.1.  Efficacy In -vivo and In -vitro Studies  ................................ ................................ ......... 24 
1.2.1.2.  Safety Pharmacology  ................................ ................................ ................................ ..25 
1.2.2.  Toxicology  ................................ ................................ ................................ .................. 25 
1.2.2.1.  Extended Single Dose Toxicity Studies  ................................ ................................ .....25 
1.2.3.  Additional Nonclinical Studies  ................................ ................................ ................... 27 
1.2.4.  Clinical Studies  ................................ ................................ ................................ ........... 28 
2. PURPOSE AND STUDY OBJECTIVES  ................................ ................................ ..30 
2.1. PURPOSE  ................................ ................................ ................................ ................... 30 
2.2. STUDY OBJEC TIVES  ................................ ................................ .............................. 31 
2.2.1.  Primary  ................................ ................................ ................................ ....................... 31 
2.2.2.  Secondary  ................................ ................................ ................................ ................... 31 
3. STUDY DES IGN ................................ ................................ ................................ .......31 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    3 CONFIDENTIAL  3.1. DESCRIPTION OF STUDY DESIGN  ................................ ................................ ......31 
3.2. DOSE RATIONALE  ................................ ................................ ................................ ..31 
3.3. DOSING  ................................ ................................ ................................ ..................... 32 
3.3.1.  Dosing Regimen  ................................ ................................ ................................ ......... 32 
3.3.2.  Intolerable Side Effect  ................................ ................................ ................................ 33 
4. STUDY ENDPOINTS  ................................ ................................ ................................ 35 
4.1. PRIMARY ENDPOINTS  ................................ ................................ ........................... 35 
4.2. SECONDARY ENDPOINTS  ................................ ................................ ..................... 35 
5. STUDY POPULATION  ................................ ................................ ............................. 36 
5.1. INCLUSION CRITERIA  ................................ ................................ ........................... 36 
5.2. EXCLUSION CRITERIA  ................................ ................................ .......................... 36 
5.3. SUBJECT IDENTIFICATION  ................................ ................................ .................. 37 
5.4. REMOVAL, REPLACEMENT OR EARLY WITHDRAWAL OF 
SUBJECTS FROM ASSESSMENT NOT DUE TO INTOLERABLE SIDE 
EFFECTS  ................................ ................................ ................................ .................... 37 
6. STUDY PROCEDURES AND ASSESSMENT  ................................ ........................ 37 
6.1. DEFINITIONS OF STUDY PROCEDURES  ................................ ............................ 37 
6.1.1.  Informed Consent  ................................ ................................ ................................ .......37 
6.1.2.  Medical History  ................................ ................................ ................................ .......... 38 
6.1.3.  Concomitant Medication  ................................ ................................ ............................ 38 
6.1.4.  Physical Examination  ................................ ................................ ................................ .38 
6.1.5.  Pain Measurement  ................................ ................................ ................................ ......38 
6.1.6.  Quality of Life and Function Measurement  ................................ ................................ 39 
6.1.7.  Vital Signs Measurements  ................................ ................................ .......................... 39 
6.1.8.  Serology Assays  ................................ ................................ ................................ .......... 39 
6.1.9.  Clinical Laboratory Tests  ................................ ................................ ........................... 39 
6.1.9.1.  Hematology  ................................ ................................ ................................ ................. 40 
6.1.9.2.  Serum Chemistry Analysis  ................................ ................................ ......................... 40 
6.1.9.3.  Urine Drug Screen  ................................ ................................ ................................ ......40 
6.1.9.4.  Urinalysis  ................................ ................................ ................................ .................... 40 
6.1.10.  ECG  ................................ ................................ ................................ ............................ 41 
6.1.11.  Draize Score  ................................ ................................ ................................ ................ 41 
6.1.12.  Photography of the Injected Site  ................................ ................................ ................. 41 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    4 CONFIDENTIAL  6.1.13.  Leg Circumference  ................................ ................................ ................................ .....42 
6.1.14.  Imaging: Ultrasound (US)  ................................ ................................ .......................... 42 
6.1.15.  Adverse Events  ................................ ................................ ................................ ........... 44 
6.1.16.  Evaluation of Response  ................................ ................................ .............................. 44 
6.1.16 .1. Evaluation of Primary Endpoints ................................ ................................ ................ 44 
6.1.16.2.  Evaluation of Secondary Endpoints ................................ ................................ ............ 45 
6.1.16.3.  Compliance Monitoring  ................................ ................................ .............................. 45 
6.1.16.4.  Dispensing of RZL -012 Investigational Product  ................................ ........................ 46 
6.1.16.5.  Questioning of Study Subjects  ................................ ................................ .................... 46 
6.2. STUDY VISITS ................................ ................................ ................................ .......... 46 
6.2.1.  Screening Procedures  ................................ ................................ ................................ ..46 
6.2.2.  Study Randomization  ................................ ................................ ................................ ..47 
6.2.3.  Study Treatment  ................................ ................................ ................................ .......... 47 
6.2.3. 1. Treatment with RZL -012 Investigational Therapy  ................................ ..................... 47 
6.2.4.  Baseline Visit  ................................ ................................ ................................ .............. 50 
6.2.5.  Subject Site Visits  ................................ ................................ ................................ .......51 
6.2.6. Termination Visit  ................................ ................................ ................................ ........ 51 
6.2.7.  Unscheduled Visit  ................................ ................................ ................................ .......51 
7. SAFETY CONSIDERATIONS AND GUIDANCE FOR 
INVESTIGATORS  ................................ ................................ ................................ .....52 
7.1. STUDY RESTRICTIONS REGARDING CONCOMITANT 
MEDICATIONS  ................................ ................................ ................................ ......... 52 
7.2. SAFETY MEASUREMENTS ................................ ................................ .................... 52 
7.3. PREMATURE DISCONTINUATION FROM STUDY ................................ ............ 53 
7.4. PREMATURE STUDY TERMINATION  ................................ ................................ .54 
7.5. DEVIATION FROM STUDY PROTOCOL ................................ .............................. 54 
8. INVESTIGATIONAL PRODUCT AND VEHICLE SPECIFICATIONS  ................ 54 
8.1. DESCRIPTION OF RZL -012 ................................ ................................ .................... 54 
8.2. FORMULATION, PACKAGING AND LABELING  ................................ ............... 54 
8.3. STORAGE AND STABILITY OF RZL -012 AND VEHICLE  ................................ .55 
8.4. DOSAGE, DISPENSING AND ADMINISTRATION OF RZL -012 AND 
VEHICL E ................................ ................................ ................................ ................... 55 
8.4.1.  Dosage  ................................ ................................ ................................ ........................ 55 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    5 CONFIDENTIAL  8.4.2.  Administration and Instructions for Use  ................................ ................................ .....55 
8.5. ACCOUNTABILITY OF RZL -012 AND VEHICLE  ................................ ............... 56 
9. ADVERSE EVENTS ................................ ................................ ................................ ..56 
9.1. ADVERSE EVENT DEFINITIONS  ................................ ................................ .......... 56 
9.1.1.  Definition of AE  ................................ ................................ ................................ ......... 56 
9.1.2.  Definition of Serious Adverse Event  ................................ ................................ .......... 56 
9.1.3.  Definition of Adverse Drug Reaction  ................................ ................................ ......... 57 
9.2. ADVERSE EVENT GRADING  ................................ ................................ ................ 57 
9.3. CAUSALITY ASSESSMENT OF ADVERSE EVENTS  ................................ ......... 57 
9.4. UNEXPECTEDNESS OF ADVERSE DRUG REACTIONS  ................................ ...59 
9.5. ADVERSE EVENT REPORTING AND MONITORING 
REQUIREMENTS  ................................ ................................ ................................ .....59 
9.5.1.  General  ................................ ................................ ................................ ........................ 59 
9.5.2.  SAE Reporting  ................................ ................................ ................................ ............ 60 
9.5.3.  Expedited Reporting  ................................ ................................ ................................ ...60 
10. STATISTICAL CONSIDERATIONS  ................................ ................................ .......61 
10.1.  STUDY DESIGN AND OBJECTIVE  ................................ ................................ .......61 
10.2.  STUDY ENDPOINTS  ................................ ................................ ................................ 61 
10.2.1.  Primary Safety Endpoints  ................................ ................................ ........................... 61 
10.2.2.  Secondary Efficacy Endpoints  ................................ ................................ .................... 61 
10.2.3.  Safety and Tolerability Endpoints  ................................ ................................ .............. 62 
10.3.  SAMPLE SIZE JUSTIFICATION  ................................ ................................ ............. 62 
10.4.  ANALYSIS SETS  ................................ ................................ ................................ ......62 
10.4.1.  Safety Analysis Set (SA)  ................................ ................................ ............................ 62 
10.4.2.  Efficacy Analysis Set (EF)  ................................ ................................ ......................... 62 
10.4.3.  Statistical Analysis of Analysis Sets ................................ ................................ ........... 62 
10.5.  STATISTICAL ANALYSIS  ................................ ................................ ...................... 63 
10.5.1.  General  ................................ ................................ ................................ ........................ 63 
10.5.2.  Subject Disposition  ................................ ................................ ................................ .....63 
10.5.3.  Demographic and Baseline Characteristics  ................................ ................................ 63 
10.5.4.  Primary Safety Endpoint  ................................ ................................ ............................. 63 
10.5.5.  Efficacy Analysis  ................................ ................................ ................................ ........ 64 
10.5.6.  Safety and Tolerability  ................................ ................................ ............................... 64 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    6 CONFIDENTIAL  10.6.  HANDLING OF MISSING DATA  ................................ ................................ ............ 64 
10.7.  INTERIM ANALYSIS  ................................ ................................ ............................... 64 
11. DATA COLLECTION, STUDY MONITORING, AND DATA 
DISCLOSURE  ................................ ................................ ................................ ............ 64 
11.1.  DATA COLLECTION AND REPORTING  ................................ .............................. 64 
11.2.  RECORD KEEPING  ................................ ................................ ................................ ..65 
11.3.  SOURCE DATA AND SOURCE DOCUMENTS  ................................ .................... 65 
11.4.  STUDY MONITORING  ................................ ................................ ............................ 66 
11.5.  CONFIDENTIALITY, DATA DISCLOSURE, AND PUBLICATION  ................... 66 
12. HUMAN SUBJECTS  ................................ ................................ ................................ .67 
12.1.  DECLARATION OF HELSINKI  ................................ ................................ .............. 67 
12.2.  INFORMED CONSENT  ................................ ................................ ............................ 67 
12.2.1.  LIABILITY AND INSURANCE CONDITIONS  ................................ ...................... 67 
13. REFERENCES  ................................ ................................ ................................ ........... 68 
 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    7 CONFIDENTIAL  LIST OF TABLES  
Table 1:  Phase 0 Clinical Trial Design  ................................ ................................ ......................... 28 
Table 2:  Subject Information and Timeframes  ................................ ................................ ............. 50 
Table 3:  RZL -012 Storage Conditions  ................................ ................................ .......................... 55 
Table 4:  Definition of Causality  ................................ ................................ ................................ ...58 
 
LIST OF FIGURES  
Figure 1:  RZL -012 Injection Design in Dercum's Disease Subjects  ................................ ............ 48 
Figure 2:  RZL -012 Injection Sites in Dercum's Disease Subjects  ................................ ................ 48 
Figure 3:  RZL -012 Injection in Lipedema  ................................ ................................ .................... 48 
Figure 4:  RZL -012 Injection Sites in Lipedema Subjects  ................................ ............................ 49 
  
 
 
 
  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    8 CONFIDENTIAL  LIST OF ABBREVIATION S 
Abbreviation or Specialist Term  Explanation  
ADR  Adverse drug reaction  
AE Adverse event  
ALP  Alkaline phosphatase  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
ATP  Adenosine triphosphate  
AUC  Area under the concentration -time curve  
BAT  Brown -like adipose tissue  
BMI  Body Mass Index  
BUN  Blood urea nitrogen  
CBC  Complete blood count  
cGMP  Current Good Manufacturing Practices  
CI Confidence Interval  
CK-MM Creatine -kinase MM  
Cmax Maximum observed concentration  
CNS  Central nervous system  
CPK  Creatine phosphokinase  
CRF  Case Report Form  
CRO  Clinical Research Organization  
CRP  C-reactive protein  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT  Dose -limiting toxicity  
EC Ethics Committee  
ECG  Electrocardiogram  
EF Efficacy analysis  set 
FDA  Food and Drug Administration  
FFA Free fatty acids  
FIFO  First In First Out  
FOB  Functional Observational Battery  
GLP  Good Laboratory Practice  
GTT P Gamma -glutamyltransferase  
HbSAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  
HED  Human equivalent dose  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    9 CONFIDENTIAL  Abbreviation or Specialist Term  Explanation  
HIV Human immunodeficiency virus  
IB Investigator’s Brochure  
IC50 Half maximal inhibitory concentration  
ICF Informed Consent Form  
ICH-GCP  International Conference on Harmonization Good Clinical 
Practice  
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
LDH  Lactate dehydrogenase  
LDL  Low-density lipoprotein  
LEFS  Lower Extremity Functional Scale  
LPL Lipoprotein lipase  
MRI  Magnetic Resonance Imaging  
NOAEL  No observed adverse  effect level  
NORD  National Organization for Rare Disorders  
PI Principal Investigator  
PK Pharmacokinetics  
PT Prothrombin time  
PTT Partial thromboplastin time  
QOL  Quality of life  
RBC  Red blood cells  
SA Safety analysis  set 
SAE  Serious adverse event  
SAT  Subcutaneous adipose tissue  
SFM  Subcutaneous fat mass  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
T1/2 Terminal half -life 
TAG  Triacylglycerols  
TG Triglycerides  
TLA  Tumescent Liposuction (Local Anesthesia)  
Tmax Time of maximum observed sample concentration  
UCP1  Uncoupling protein 1  
US/USA  United States/United States of America  
WAL  Water Assisted Liposuction  
WAT  White adipose tissue  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    10 CONFIDENTIAL  Abbreviation or Specialist Term  Explanation  
WBC  White blood cells  
 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    11 CONFIDENTIAL  STATEMENT OF COMPLIANCE  
This clinical trial will be conducted in compliance with the protocol, International Conference on 
Harmonization Good Clinical Practice E6 and the applicable regulatory requirements.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    12 CONFIDENTIAL  INVESTIGATOR SIGNATURE PAGE  
I have read and understood the protocol and agree to implement the study in accordance with the 
proced ures set forth in the protocol and in accordance with the Sponsor's guidelines, all 
applicable government regulations and the International Conference on Harmonization Good 
Clinical Practice Guidelines E6 (ICH -GCP).  
I will provide adequate protocol trainin g to my associates, colleagues and employees assisting in 
the conduct of the study.  
I will obtain Institutional Biosafety Committee (or equivalent) and Institutional Review Board 
(IRB)/Ethics Committee (EC) approval of the protocol and the Subject Informe d Consent form 
prior to enrollment of subjects in the study.  I understand that any modifications to the protocol 
made during  the study must first be approved by the Institutional Biosafety Committee (or 
equivalent) and IRB/EC except when such modification  is made to remove an immediate hazard 
to the subject.  
I will ensure that a fully executed Subject Informed Consent form is obtained from each subject 
prior to initiation of any study procedures.  
I will report (within 24 hours) any serious adverse event that occurs during  the study in 
accordance with the procedures described in Section 9 of the protocol.  
I will allow the S ponsor, Raziel Therapeuti cs Ltd. and its agents, as well as the United States 
(US) Food and Drug Administration (FDA) and other regulatory agencies, to inspect study 
facilities and pertinent records at reasonable times and in a reasonable manner, ensuring subject 
confidentiality .  If I am notified that this study is to be inspected by a regulatory agency, I will 
notify the Sponsor as soon as possible thereafter (no later than one week).  
 
 
 
 
_Karen L. Herbst _______   __ __________________    _10/22/2019 _ 
Investigator's name    Investigator’s Signature    Date  

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    13 CONFIDENTIAL  PROTOCOL SYNOPSIS  
Protocol 
Number  RZL -012-FD-P2aUS-001 
Protocol Title  An open label, phase 2a clinical trial for the evaluation of safety and efficacy of RZL -012 for the 
treatment of wome n with lipedema involving substantial  fat above the knee or  women and men with 
nodular Dercum's disease.  
Study Phase  Phase 2a  
Study Drug  RZL -012 
Study 
Objectives  Primary objective :  Evaluation of the overall safety of RZL -012 following injection into the 
subcutaneous fat in patients with lipedema.  
Secondary objective :  Evaluation of local fat reduction, its extent, duration and tissue associated 
changes, in response to RZL -012 treatment, utilizing minimal invasive means (ultrasound) fol lowing 
subcutaneous injection of RZL -012 into fatty tissue below the skin.  
Sample Size  12 subjects  
Study Design  This is an open label, 2 cohort clinical trial in women with lipedema with substantial fat above the 
knee or women and men with nodular Dercum's disease.  Each cohort will have 6 subjects who will 
receive RZL -012. 
• The 1st cohort will be comprised of subjects with Dercum's disease  
• The 2nd cohort will be comprised of subjects with lipedema with substantial fat above the 
knee .  
Within each co hort, dosing of the subjects will progress consecutively from one individual to the 
other with a minimum of 7 -days between subjects to assess safety. This study design will allow the 
physicians to  monitor safety for at least 7 days prior to dosing the next  subject. Cohort 2 will be 
conducted in a dose escalation manner and the decision to proceed to the next dose level will be 
made after reviewing all safety data collected by Day 14 within 2 ± 1d of the last dosed subject. The 
trial will proceed within a co hort provided that no more than one subject experiences intolerable side 
effects in a cohort, and based on the decision made by the Principal Investigator ( PI) and the Medical 
Monitor .   
Study 
Population  Post-menopausal women no more than 65 years old, wi th lipedema involving  substantial fat above 
the knee or nodular Dercum's disease  in such women and in men 20- 65 years with nodular Dercum's 
disease . 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    14 CONFIDENTIAL  Main Inclusion 
Criteria  
 Subjects must meet all the following to be eligible for study participation:  
1. Post-menopausal (at least 2 years) women no more than 65 years old, with lipedema involving 
substantial fat above the knee  or nodular Dercum's disease  in such women and in men 20  - 65 
years with nodular Dercum's disease .  
2. For Dercum's diseas e subjects – at least 2 nodules to be injected of at least  2cm diameter, each, 
as determined by ultrasound  
3. For lipedema subjects - Significant subcutaneous fat above the knee as determined by 
circumference of 50cm  
4. Generally considered healthy according to medical history, physical examination, 
electrocardiogram (ECG) and laboratory evaluation with a special emphasis on metabolic 
parameters (fasting glucose concentration < 200 mg/dL, normal blood pressure).  
5. Subjects must be able to adhere to the visit schedule and protocol requirements and be available 
to complete the study.  
6. Subjects must sign an informed consent indicating that they are aware of the investigational 
nature of the study.  
Main Exclusion 
Criter ia Subjects meeting any of the following criteria will be excluded:  
1. Unable to tolerate subcutaneous injection.  
2. Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that in the 
opinion of the investigator put the subject a t significant risk, are not eligible.  
3. Positive blood screen for  Hepatitis B surface antigen  (HbSAg ), Hepatitis C virus (HCV), or 
Human immunodeficiency virus (HIV) , or positive urine screen for alcohol or drugs of abuse 
(unless prescribed by a physician).  
4. Subjects with a clinical history of primary or secondary immunodeficiency, autoimmune disease 
or subjects taking immunosuppressive drugs such as corticosteroids are ineligible.  
5. As a result of medical review, physical examination, the PI (or medically qualified nominee) 
considers the subject unfit for the study.   
6. Known sensitivity to components of the injection formulation.  
7. Prior wound, tattoo or infection in the treated area.  
8. Prior invasive treatment such as surgery or injectable drug at the RZL -012 injected area.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    15 CONFIDENTIAL  Intolerable Side 
Effect Definition  An intolerable side effect defined as any of the following treatment -related adverse drug reactions 
(ADRs):  
• Any Grade 3 or greater event except for the following (For the following events, a 
discussion will be held by the P I and the Medical Monitor  to decide whether considered as 
an intolerable side effects):  
o Flu-like symptoms and fever that responds to standard treatment within 72  hours  
o Localized edema and erythema  
o Pruritus  
o Pain 
o Skin/soft tissue inflammation  
o Fat Atrophy  
o Liver enzymes abnormality  
o Non-significant lab abnormalities, lasting less than 7 days  (See Section 3.3.2)  
Subjects experiencing a n intolerable side effect  will be withdrawn from the study, but followed until 
the event  resolves or becomes stable ; all actions taken are to be fully documented in source 
documents and Case Report Forms (CRFs).  To be considered a n intolerable side effect , such an 
event must be considered to be possibly or probably related to the study drug  
The study may also be prematurely terminated in any of the following cases:  
• Recurring serious or severe ADR clinically evaluated by PI as warranting study termination.  
• A decision made by Sponsor and/or Institutional Review Board ( IRB)/Ethics Committee 
(EC) and/or local regulatory agency to terminate the study.  
Study Drug 
Dosage and 
Administration  The 1st cohort will be comprised of subjects with Dercum's disease: all subjects will be injected with 
RZL -012. Dosing will be calculated according to the size of the nodule (diameter) as determined by 
ultrasound: 5mg/cm2 reaching a maximal dose of 40mg per subje ct (1/6.25 the No observed adverse 
effect level [ NOAEL ] based on Human Equivalent Dose [HED ] from Good Laboratory Practice 
[GLP ] toxicology study).  
Nodule of 2 -2.9cm diameter, as determined by ultrasound, will be injected 2 injections (0.1 mL each , 
1 cm a part) ; total of 10  mg RZL -012.  
Nodules of 3 -3.9cm diameter, as determined by ultrasound, will be injected 3 injections (0.1 mL 
each, 1 cm apart) ; total  of 15  mg RZL -012.  
Nodules of 4 -8cm diameter, as determined by ultrasound, will be injected 4 injection s (0.1 mL each , 
1 cm apart) ; total  of 20  mg RZL -012. 
 
Cohort 1  
Number of Subjects – Active  6 
Nodule size – diameter (cm)  2-2.9 3-3.9 4-8 
Total Dose of RZL -012 (mg)  10 15 20 
Dose per NOAEL*  1/25th 1/18.75th 1/12.5th 
Number of Injections  2 3 4 
 
Subjects will receive a single treatment in multiple sites (2 -8) of injection according to the design in 
the picture below:  
 

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    16 CONFIDENTIAL  Injections will be diagonally (45 °) to the skin surface and towards the center of the nodule and t he 
distance between injections  in a nodule will be 1  cm (see picture below).  
 
The 2nd cohort will be comprised of subjects with lipedema with substantial fat above the knee .  
The first 3 subjects will receive 30 mg RZL -012 in 6 injections (0.1mL each) in on e leg followed by 
30mg RZL -012 ( 6 injections, 0.1mL each) in the second leg adding up to 12 injections of 60mg 
RZL -012 (1/ 4.688th the NOAEL based on HED from GLP toxicology study).  
The last 3 subjects will receive 40mg RZL -012 in 8 injections (0.1mL each) in one leg followed by 
40mg RZL -012 (8 injections, 0.1mL each)  in the second leg adding up to 16 injections of 80mg 
RZL -012 (1/3.125th the NOAEL based on HED from GLP toxicology study).  
  
 
 
 
 
 
 
* based on HED from GLP toxicology study  
 
A grid line will be drawn with a makeup pencil in a horizontal plane (Figure 2) 4-6 cm from the 
suprapatellar fat and its distance from the floor recorded. An attempt should be made to find palpable 
nodules along the grid line. The injection sites will be marked in circles with a non -erasable pen. This 
mark should be intensified upon following visits. Injections will be give n in multiple sites (4 -8 in 
each leg), diagonally (45 °) to palpable nodules, in the fat above the knee .  An attempt should be 
made to lift the nodule and inject into the middle of the fat -mass. If no nodules are noted in the 
horizontal plane, drug will be  injected in to the fatty tiss ue (in this case small nodules seen in 
ultrasound will be followed for changes ). Injections will be on the same horizontal plane.  
 
 Cohort 2  
Number of Subjects – Active  3 3 
Total Dose RZL -012 (mg)  60 80 
Dose per NOAEL*  1/4.688  1/3.125  
Number of Injections  12 16 

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    17 CONFIDENTIAL  Injections will be spread as much as possible and the distance between injected sites will be at least 
2-3 cm, according to the number of injections (see picture below).  
Concomitant 
Medication  All concomitant medication given 1 month prior to study entry, including blood and blood products, 
dietary supplements, and non-prescription drugs will be listed at screening/baseline.  The clinical 
significance of the medication use will be decided by the investigator.  Study subjects will be 
routinely questioned for changes in the administration of concomitant medication duri ng the trial  and 
changes should be updated from medical records as well .  
Subjects may not receive the following medications while on study:  
• Chronic treatment with systemic steroids or immunosuppressive drugs.  
•  Chronic treatment with Non Steroid Anti -Inflammatory Drugs (NSAIDs) and aspirin.  
• Any investigational product other than RZL -012.  
Before dosing, analgesic gels or creams such Lidocaine (e.g., Emla) or Pramoxine should be used to 
numb the injected site.  A n ice pack may be applied on the site of injection following dosing to help 
reduc e pain.  At day 1 followin g injection , application of  the anti -histamine Benadryl Gel 
(Diphenhydramine hydrochloride 1 % for topical use only ) should be initiated prophylactica lly, 
according to drug instructions for use , to avoid itching at the injected area.  Benadryl Gel should be 
applied for 7 days.  
Use of nattokinase is prohibited and the use of other supplements or complementary 
medicines/botanicals  should be approved by th e PI, except for conventional multivitamin 
supplements.  The use of prohibited supplements should be stopped a week before injection.  
Study 
Procedure  Study activities upon study entry will include, but not be limited to:  
Informed Consent, full medical history, physical examination, vital signs measurements, ECGs, 
clinical laboratory tests, photography and skin irritancy evaluation of site injection , ultrasound, 
height and weight measurements, Quality of Life ( QOL ) and function questionnaire  in lipedema 
subjects , and pain assessment . 
Periodical site visits will allow assessment of treatment safety and efficacy.  
Subjects will be advised to keep their regular diet and physical activity.  
Visit Schedule  
(See Table 2) 
 Subject site visits will be performed ± 1 day from scheduled date  for study visits Day 0 -28 and 2± 1 
days from schedule date for follow -up visits (Da y 56).  All data relevant for the visit needs to be 
obtained within 3 days (e.g., blood tests results) of visit.  
Screening Day visit (Day -14 through -2): 
- Following signing the informed consent - assessment of subject eligibility will include: 
medical his tory, physical examination, vital signs, ECG, serology assays (HBV, HCV and 
HIV), clinical laboratory tests, drug screen.   
Clinical laboratory tests will include:  

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    18 CONFIDENTIAL  1. Hematology:  Complete blood count (CBC ) including White blood cell [WBC] different ial 
values, Fibrinogen , and coagulation (International normalized ratio [INR], Partial 
thromboplastin time [PTT]  and Prothrombin time [PT]). 
2. Serum chemistry analysis:  sodium, calcium, potassium, phosphorus, glucose, liver 
enzymes (Aspartate aminotransferase [AST], Alanine aminotransferase [ALT], Lactate 
dehydrogenase [LDH], Creatine -kinase MM [CK -MM], Gamma -glutamyltransferase  
[GTTP], Alkaline phosphatase [ALP]), Bilirubin, Creatinine, Blood urea nitrogen [BUN ], 
Total protein, Albumin, Amylase, Creatine phosphokinase [CPK], C-reactive protein 
[CRP ]). 
3. Urinalysis: Nitrite, Sodium, Potassium, Calcium, Phospha te, Protein, Red blood cells 
(RBC ), WBC, Blood, Glucose, Ketone bodies, Bilirubin, Urobilirubin, Urine specific 
gravity, Osmolality , and pH.  
- In addition, photography and evaluation of skin irritancy by Draize score of the injection 
site area.  
- For Dercum's disease subjects – ultrasound assessing nodules size (diameter) and quality. 
Determining which nodules are to be injected with a total of 40mg RZL -012. 
- For lipedema subjects – measurement of leg circumference above the knee and assessing fat 
thickness and nodular quality by ultrasound.  
- For lipedema subjects - QOL and function questionnaires.  
Baseline visit (Day 0 ):  
- Pre-treatment: eligibility confirmation, vital signs, Draize score, leg circumference, clinical 
evaluation of local pain and tenderness to pres sure and nodules size and/or numbe rs, blood 
sample for serum chemistry, and hematology baseline level will be taken.  
- Treatment - All injections will be administered 45 ° to the skin surface using a 1  mL Luer -
lock syringe and a 30 G x 1/2" needle (the hole  of the needle pointing into the fat layer).  
- Post treatment: ECG (4h and 8h ± 30min post injection), pulse rate (1h, 2h, 4h, 8h,  24h post 
injection in the opposite hand of blood sampling), vital signs (2h ± 30  min post injection), 
Draize score (2h post injection ± 30 min), adverse events (AEs) will be recorded.  
Schedule visits (Day 1-28): 
- Day 1 following treatment will include: ECG, vital signs including pulse rate, Draize score, 
and photographs of the treated area, clinical evaluation of local pain and ten derness to 
pressure. Subjects will start applying an anti -histamine gel.  
- For safety reasons 24hr ± 2hr following inj ection, Blood samples for serum chemistry and 
hematology will be taken  
- Day 3 following treatment will include Serum che mistry and hematology .   
- Visits will take place every 7 days ± 1d from treatment till Day 28.  During visits,  all tests 
(physical exam, v ital signs, ECG, clinical laborator y tests, urinalysis, Draize score, leg 
circumference above the knee,  weight measurement,  QOL and function questionnaires  in 
lipedema subjects , clinical evaluation of local pain and tenderness to pressure and reduction 
in nodules size and/or numbers, photographs and ultrasound will be performed according to 
schedule ( Table 2). 
- Subjects will be questioned for AEs every visit.  
- Subjects will record their daily use of analgesics . Diaries will be checked and data will be 
captured in the CRFs.  
Follow -up visit (Day 56):  
- Subjects will be followed on Day 56 following injection.  
- A week before Day 56 visit, subjects will record their daily use of analgesics . Diaries will be 
checked and data will be captured in the CRFs.  
- Evaluation of the injected area will be performed by Draize score, photographs, QOL and 
function questionnaires  in lipedema subjects , clinical evaluation of local pain and tenderness 
to pressure and reduction in nodules size and/or numbers.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    19 CONFIDENTIAL  - For Dercum's disease subjects – ultrasound assessing nodules size (diameter) and quality.  
- For lipedema subjects – measurement of leg circumference  above the knee  and assessing fat 
thickness and nodular quality by ultrasound.  
- Subjects will be questioned for AEs. 
Safety Analysis  Safety data from the study will be summarized descriptively by treatment and cohort.  Descriptive 
statistics will be calculated for quantitative data and frequency counts and percentages will be 
provided for categorical data.  The nature, frequency, seriousness, severity and relation to study drug 
of AE s will be tabulated for all s ubjects combined and by treatment.  Change -from -baseline values 
for vital signs, clinical laboratory and ECG will be summarized.  Shift tables of normal / abnormal 
versus baseline may be presented as well. Draize scores will be presented in tabular format by visit, 
treatment, and cohort. Serious adverse events ( SAEs ) will be described in narratives as part of the 
study report.  
Study 
Endpoints  Primary Endpoint : 
Evaluation of the overall safety of RZL -012 injection into the subcutaneous fat in Derdum's 
disease and lipedema.  
The primary safety endpoint is the incidence of intolerable side effects.  
Secondary Endpoints : 
1. For lipedema subjects - The reduction in local subcutaneous fat in the injection site region as 
compared to baseline based on ultrasound (reduction in nodules size and/or numbers) and  leg 
circumference above the knee assessments.  
2. For Dercum's disease subjects - The reduction in local subcutaneous fat in the injection site 
region as compared to baseline based on ultrasound (reduction in nodules size and/or numbers).  
3. Extended duration of the fat reduction effect.  To that end, ultra sound images and above the knee 
circumference measurement will be followed for 56 days.  
4. Elucidation of the tissue changes by ultrasound of the injection site to include reduction in fat 
thickness and nodular quality.  
5. Improvement in local pain as measured b y Comparative Pain Scale and by the reduction in the 
use of analgesics . 
6. Improvement in QOL  and function in lipedema subjects as measured by questionnaire (such as 
The Lower Extremity Functional Scale (LEFS)).  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    20 CONFIDENTIAL  Sample Size  This study is planned as a Phase 2a trial. A maximum of 12 evaluable subjects will be included in the 
study (6 Dercum's disease subjects and 6 lipedema subjects) and followed for as long as 56 days.  
Statistical 
Methods  Statistical analyses will be mainly descriptive in nature where study data will be tabulated and 
summarized using the mean, standard deviation or standard error, median, minimum, maximum and 
number of subjects by cohort for continuous data.  For categorica l data, results will be summarized 
via a count and percentage by cohort.  The results will be presented overall, per cohort and per cohort 
and do se. The effects of noncompliance, dropouts, and covariates may be assessed to determine the 
impact on the gener al applicability of results from this study.  
If any statistical tests are performed, they will be two -sided.  The required significance level of 
findings will be equal to or lower than 5%.  Nominal p -values will be presented.  
Where confidence limits are ap propriate, the confidence level will be 95%.  
Incidence of intolerable side effects will be tabulated by study drug by cohort along with 95% 
confidence intervals.  
Change from baseline will be presented in a tabular form by visit treatment.  
AEs and tolerabil ity data will be presented descriptively by treatment and cohort.  AEs will be 
tabulated by body system, preferred term, seriousness, severity and relation to study drug by cohort.  
Where applicable, changes in values over time (e.g., lab values, vital sig ns, ECGs) will be presented ; 
this will include clinical laboratory evaluations (including CBC, blood chemistry and urinalysis), 
coagulation (INR, PTT and PT), vital signs, and ECGs.  Shift tables of normal / abnormal versus 
baseline may be presented as wel l. 
Draize scores will be presented in tabular format by visit, treatment, and cohort  
Study Duration  Study duration is 2.5 months, including enrollment, treatment and follow -up period.  
Each subject will participate in the study for up to 42 days as part of this protocol.  
Study Site  University of Arizona Medical Center, Tucson, Arizona  
 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    21 CONFIDENTIAL  1. INTRODUCTION  
1.1. BACKGROUND  
1.1.1.  Scientific Background and Clinical Rationale  
Obesity, a  major health concern today , is a direct result of food -intake in excess of body energ y 
expenditure.  However , there is a vast amount of published information that proves that for some 
people, obesity is not the result of excessive food consumption, poor food choices, and failure to 
exercise  (1). Problems with mitochondria, leaky lymphatics and other mutations can drive and 
maintain fat growth that cannot be lost through traditional diet and exercise  (2). Dercum’s 
Disease (Adiposis Dolorosa), Madelung’s Disease, lipede ma and Familial Multiple Lipomatosis 
or Angiolipomatosis are names of some of such fat disorders. These are known as Rare Adipose 
Disorders ; they a re painful, progressive disorders that result in abnormal accumulations of fat in 
the form of lipomas, excess  lymphatic fluid, and many other symptoms.  
Lipedema is a chronic condition , initially described in 1940, that occurs almost exclusively in 
women and manifests as symmetrical buildup of painful fat and swelling in the limbs, sparing the 
hands and feet  (3). Fat tissue expands primarily in th e lower limbs, from buttocks to ankles, as 
well as in the arms . Upon palpation of the fat , tiny pebbles or pea like nodules  are felt . As the 
disease advances the nodules may increase in size and in number and may form strands of 
nodules (4). There are no diagnostic tools or tests for lipedema. Diagnosis of lipedema involves a 
clinical asses sment and discussion of the individual’s medical history, a process that is difficult 
to scale within the current healthcare system. The absence of diagnostic tools to streamline or 
confirm a clinical diagnosis is a key unmet need, which if addressed, has the potential to 
dramatically change the trajectory of the disease  (5). Individuals who suffer from the d isease are 
further impacted by the lack of public and medical awareness of lipedema, and the stigma 
associated with weight gain. As a result, the epidemiology of lipedema  is unknown  (6).  
The etiology of  lipedema  and other types of fatty tissue enlargement is still unknown , though a 
genetic cause is suspected.   Other possible causes of  lipedema  include metabol ic, inflammatory, 
or hormonal involvement. Although the disease is reported to occur during puberty and other 
periods of hormonal changes, why this happens is not understood .  
Lipedema is sometimes accompanied by co -morbidities, often secondary diseases, w hich 
complicate the patient’s health. Psychosocial issues are prevalent in women with lipedema, 
contributing to health burden and complexity of disease management. The painful fat and 
swelling in some patients can be so debilitating that their mobility is impaired. Furthermore, 
many patients develop the disease alongside obesity; however, diet, exercise, and weight loss 
surgery have limited effect on lipedema fat . 
A critical issue is the p oorly understood disease , which for diagnosed patients results in limited 
treatment options that, at best, ameliorate the symptoms of lipedema . Early detection and 
treatment can significantly reduce the debilitation of the patient.   Early weight and diet changes 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    22 CONFIDENTIAL  through  nutrition  and exercise  may be helpful in reducing n on-lipedemic fat and 
reducing  inflammation.   This approach may possibly prevent the lower body from enlarging as 
much as it would if the patient were to become obese. However, even with strict diet and 
exercise regimens the disease may progress and furthe r treatments may be necessary. While there 
is no proven effective treatment for lipedema, the swellin g may be somewhat managed with 
compression garments, manual lymphatic d rainage  and/or  Complete Decongestive 
Therapy.   Unfortunately, some products such as  garments may not be well tolerated by all 
patients if the patient exp eriences pain.  Liposuction  as a treatment for lipedema was develope d in 
Germany in the late 1980s and is becoming more common. However, g iven the fact that 
liposuction is a surgery , it is not a risk-free procedure .  While it has helped some patients when 
done by a skilled surgeon knowledgeable about lipedema, very few physicians in the United 
States have the knowledge and experience of physicians in Europe . Currently, different 
liposuction procedures (Water Assisted Liposuction [WAL ] and Tumescent Liposuction [TLA ]) 
used for lipedema patients are available but not all surgeries are suitable for all patients  (7).  
Dercum's disease  was first described in the medical literature in 1882 by an American 
neurologis t named Francis Xavier Dercum’s.  Dercum’s disease is an extremely rare disorder 
(listed by NORD [National Organization for Rare Disorders ]) characterized by multiple, painful 
growths consisting of fatty t issue (lipomas). These growths mainly occur on the trunk, the upper 
arms and upper legs and  are subcutaneous . Pain associated with Dercum's disease can often be 
severe. Pain may be caused by these growths pressing on nearby nerves.  Some individuals with 
Dercum’s may experience swelling of various areas of the body, especially the hands. Swelling 
occurs for no apparent reason and often disappears without treatment. In some cases, affected 
individuals may also experience weight gain, depression, lethargy, and /or confusion.   
The etiology of  Dercum's disease is unknown , though a genetic cause is suspected (autosomal 
dominant).   Other possible causes playing a role in the development of  Dercum's disease  include 
autoimmune disorder, disturbances in endocrine funct ion, improper metabolism of fat  and the 
use of high -doses of corticosteroids.  
The prevalence of Dercum’s disease is unknown. Dercum’s disease affects females more often 
than males with some reports citing the disease is as 20 times more common in women. 
Dercum’s disease can affect individuals of any age. The majority of cases are women between 
the ages of 45 -60, especially overweight, postmenopausal women.   
No specific treatment exists for Dercum’s disease. Treatment is mainly symptomatic and 
supportive and  is primarily focus ed on easing the characteristic painful episodes.  Various 
analgesics have been tried with limited effectiveness . Surgical excision of fatty tissue deposits 
around joints may temporarily relieve symptoms although recurrences often develop. 
Liposuction has been used as a supportive treatment for some individuals with Dercum’s disease 
and may provide an initial reduction in pain and improvement in quality of life  (QOL)  (8). These 
effects may lessen over time. Psychotherapy and consultation with pain management specia lists 
may be helpful for enabling affected individuals to cope with long -term intense pain.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    23 CONFIDENTIAL  RZL -012 is a novel synthetic molecule enabling the conversion of white adipose tissue (WAT) 
into an activated thermogenic tissue at targeted anatomical sites.  A si ngle injection of RZL -012 
into WAT is sufficient to trigger robust tissue remodeling.  A chain of events begins with 
removal of WAT adipocytes by macrophages (liponecrosis), followed by an activation of 
remodeled cells that generate a futile cycle of ongoi ng energy conversion into heat. Temperature 
measurements of the site treated by RZL -012 reveal a persistent local increase in temperature 
(about 4 months in pigs).  As long as these cells are active, the ensuing thermogenic tissue will 
consume free fatty ac ids (FFA) from the near by surrounding adipose depots  and further from 
glucose and FFA supplied via the blood stream.   
The overall clinical plan for RZL -012 includes the completed exploratory (phase 0) study to 
evaluate the safety, thermogenesis, and pharma codynamic response to RZL -012.  An additional 
phase 2 study (Study RZL -012-P2aUS -001.1 ) in overweight and obese subjects to confirm the 
safety and pharmacodynamic effects of RZL -012 for the treatment of obesity will be initiated 
soon to explore the respons e to higher doses prior to the initiation of larger studies.  The initial  
exploratory study ( Study RZL -012-P0US -001.3 ) demonstrated that RZL -012 is well tolerated 
with no serious adverse events reported and that thermogenesis was evident at the injection site 
(abdomen) of RZL -012-treated obese subjects.  Although not statistically significant (due to the 
initially tested l ow dose and a small -size study group, n=6), there was a decrease in subcutaneous 
fat mass (SFM) over time (compared to baseline) in the abdomen, as measured by Magnetic 
Resonance Imaging ( MRI ), in 5 out of 6 RZL -012 treated subjects , but none in vehicle tr eated 
ones. 
Raziel Therapeutics  believe s that RZL -012 effects of adipose -tissue replacement thermogenic 
tissue and the ongoing lipolysis and consumption of FFA from nearby adipose tissue by the 
remodeled cells can be beneficial to patients with fat disorde rs such as lipedema and Dercum's 
disease . Local fat reduction and tissue remodeling at selected sites such as at  the medial knee in 
lipedema patients and at lipomas in Dercum's disease patients may bring pain relief and 
improvement in QOL .  
The current Phase 2a study is aimed to evaluate the safety and pharmacodynamics response to 
RZL -012 in lipedema and Dercum's disease patients.  
 
1.1.2.  RZL -012 Formulation Development  
The active ingredient RZL -012 drug substance was manufactured by Pharmacore , High Point 
NC, USA .  The drug product, 5 % RZL -012 in F12 liquid formulation (RZL -012 in F12 is 5 
g/vial, RZL -012 is 250  mg/vial) was manufactured and packed at Nextar Ltd, Ness -Ziona, Israel.  
RZL -012 in F12 , which was once defined as RZL -012 F12 , is now defined as RZL -012.  The 
active ingredient and formulation manufacturing and packing were in accordance with current 
Good Manufacturing Practices (cGMPs).  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    24 CONFIDENTIAL  1.2. NONCLINICAL ASSESSMENTS  
1.2.1.  Pharmacology  
Studies in rats and pigs concluded that RZL -012 triggers remodeling of WAT to brown -like 
adipose tissue ( BAT ) tissue , thereby activating thermogenesis.  The dose of RZL -012 to be  used 
in clinical trials was extrapolated from the safety data obtained during animal testing  no observed 
adverse effect level (NOAEL) . 
1.2.1.1.  Efficacy In -vivo and In-vitro Studies  
Nonclinical studies were conducted to prove the efficacy of RZL -012 in several in -vivo and in -
vitro models.  
The in vivo studies (in pigs and rats) involving local administration of RZL -012, focused on two 
main endpoints: fat tissue reducti on and conversion of WAT to BAT , measured by several 
parameters, including;  
1. Subcutaneous or epididymal fat reduction following RZL -012 treatment.  
2. Fat tissue remodeling involving non -inflammatory liponecrosis , followed by tissue 
"browning", where WAT is converted to BAT  in rodents and smooth -muscle -like tissue 
in larger mammals .  This conversion can be determined by:  
a. Histological fat tissue changes:   While white adipocytes are large and resemble a 
single large  oil drop, with a characteristic condensed nucleus, the cells of BAT are 
smaller, contain multiple mitochondria and a euchromatic nucleus.  
b. Uncoupling protein 1( UCP -1) levels:  UCP -1 is a mitochondrial inner membrane 
protein present in BAT that can dissipate the proton gradient before it can be used 
to provide the energy for oxidative phosphorylation .  UCP -1 normally does not 
exist in WAT.  
c. Smooth -muscle -like thermogenic tissue : In pigs, examination of tissue -sections 
taken from the site of injection, where robust thermogenesis was observed, 
revealed smooth -muscle -like histology, including typical molecular markers such 
as SMA.   
3. Assessment of body -surface temperature: Thermogeni c tissue, e.g. classical BAT,  is 
typified by futile burning of fatty acids (i.e., heat production instead of adenosine 
triphosphate [ ATP ]), which can be assessed utilizing  infrared camera that can measure 
differences in body surface temperature.  
The object ive of the in -vitro studies was to reveal the mechanism of action of RZL -012 in 
adipocytes.  Studies were conducted on the 3T3 -L1 adipocytes line, which is considered a model 
for WAT .  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    25 CONFIDENTIAL  1.2.1.2.  Safety Pharmacology  
The effect of RZL -012 on the central and peripheral  nervous systems was evaluated using the 
Functional Observational Battery (FOB) in male Sprague Dawley rats.  RZL -012 was 
administered subcutaneously to rats (n  = 8/group) as 10 mg/rat.  From the results,  it was 
concluded that RZL -012 did not affect any of  the central nervous system ( CNS ) functions tested 
using FOB  in rats.  
The effect of RZL -012 was evaluated on respiratory functions in male Sprague Dawley rat s 
using head -out plethysmography.  RZL -012 was administered subcutaneously at a fixed dose of 
10 recorded to cover the entire predetermined time points : Pre-dose, 1, 2, 3, and 4 h post dose.  
RZL -012 did not affect any of the parameters tested ; hence it was  concluded that RZL -012 has 
no effects on the respiratory system at the tested dose of 10 mg/rat.  
A board -certified veterinary cardiologist conducted a qualitative and quantitative review of the 
electrocardiograms (ECGs) obtained pretest, pre -dose, 4 and 24 hours post -dose following the 
subcutaneous injection of 500 mg 5.0 % RZL -012 or vehicle in Domestic Yorkshire Crossbred 
Swine.  There was no effect of the subcutaneous injection of 5.0 % RZL -012 on qualitative or 
quantitative ECG parameters or blood pre ssure.  
1.2.2.  Toxicology  
The study design was to evaluate the safety of RZL -012 according to Food and Drug 
Administration ( FDA ) guidelines for Exploratory Investigational New Drug ( IND) appropriate 
for first -in-man clinical trial.  An extended single -dose toxicit y study was performed according 
to FDA guidance in two species (rat and pig) to establish the NOAEL.  
1.2.2.1.  Extended Single Dose Toxicity Studies  
1.2.2.1.1.  Rats  
Single subcutaneous administration of test item RZL -012 at the doses of 5, 10 , and 20 mg/kg in 
Sprague -Dawley ra ts resulted in non -systemic effects and or local effects at the treated skin area.  
Few changes observed in haematological parameters ( white blood cells [ WBC ] count, 
neutrophils, monocytes and eosinophils) were considered secondary effects due to inflammat ory 
response (local skin reactions).  The changes observed in clinical chemistry parameters 
(increased blood urea nitrogen [ BUN ] in males and females and increased creatinine and 
aspartate aminotransferase [ AST ] levels in females) at all the doses tested a nd histopathological 
changes in kidneys (necrosis in tubular epithelium) at 20 mg/kg were considered systemic 
effects.  Methods and results from the extended single dose toxicity study are described in the 
Investigator's Brochure  (IB). 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    26 CONFIDENTIAL  Considering skin cha nges as non-systemic effects and or local effects, the NOAEL was 
determined at 5 mg/rat with an average body weight of 258.9 g , under the test conditions and 
doses employed.  
1.2.2.1.2.  Pigs 
This study was conducted to evaluate the potential local and systemic toxicity as well as efficacy 
of the test article, RZL -012 (50 mg/mL), in domestic Yorkshire crossbred swine following 
subcutaneous injection into the subcutaneous abdominal fat on Day  0.  Methods and results from 
the extended single dose toxicity in pigs study are described in detail  in the IB. 
Assessment of toxicity was based on mortality, clinical observations, body weight, qualitative 
food consumption, body temperature, subcutaneous fa t temperature, blood pressure , physical and 
electrocardiographic examinations , and anatomic and clinical pathology.  Blood samples were 
collected and analyzed for porcine stress syndrome te sting  and toxicokinetic assessment of the 
test article.  
Administration of the test article was not associated with any mortality, clinical observations 
(with the exception of transient redness and swelling at injection sites), body weight or food 
consumption changes, effects on electrocardiographic endpoints, o r changes in clinical chemistry 
or coagulation parameters.  It should be noted that three animals died during the post anesthesia 
recovery period.  The cause of death was considered to be related to perioperative complications 
associated with the anesthesi a and not related to RZL -012 or saline administration.  These three 
animals were replaced on study.  This nonclinical laboratory study was conducted in accordance 
with the United States Food and Drug Administration (FDA) Good Laboratory Practice (GLP) 
Regu lations, 21 Code of Federal Regulations (CFR) Part 58 and the Organization for Economic 
Cooperation and Development (OECD) Principles on GLP [as revised in 1997; 
ENV/MC/CHEM(98)17].   A complete postmortem necropsy was conducted on these dead pigs, 
and prot ocol-designated tissues were saved and processed for microscopic evaluation  under 
ambient conditions to Alizée Pathology, Thurmont, Maryland.   Two of these animals were 
controls and one treated. Pigs are very sensitive to anesthesia and these were complica tions due 
to it. Attached is the study report - you can find mortality results and discussion on page 26 -27. 
A slight elevation in body temperatures was noted in males treated with the test article from 
Days 14 -16 until Days 77 -79.  In addition, several an imals were observed with perioperative 
hyperthermia and/or hypothermia.  To determine if the perioperative hyperthermia and/or 
hypothermia was caused by Porcine Stress Syndrome all remaining animals on study were tested 
and determined to be normal (negativ e). 
Administration of the test article was associated with changes in subcutaneous fat temperatures, a 
mild increase in neutrophils, and macroscopic and microscopic observations.  
A noticeable difference in subcutaneous fat temperatures was noted between t reatment groups.  
Beginning as early as Day 4 -5, an increase in temperature was noted at all test article treated sites 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    27 CONFIDENTIAL  in both males and females.  The increase in temperature was noted through Days  58-63.  At 
study termination, subcutaneous fat temperatur es at treated sites were comparable to vehicle 
control.  
Subcutaneous administration of RZL -012 (50 mg/mL) to farm pigs resulted in mild increases in 
neutrophils in both sexes at the 24-hour post-dose collection, which were most typical of an 
inflammatory r esponse.  Increases in neutrophils had resolved by the Day 14 collection.  
Analysis of the plasma samples following subcutaneous administration of RZL -012 (Group  4) 
found that both female and male farm pigs were exposed to RZL -012.  Mean systemic exposure 
(area under the concentration versus time curve between zero and the 24 hour time point  
[AUC 0-24hr]) and maximum observed concentration (C max) values, were 3700 (hr*ng/mL) and 
529 (ng/mL), respectively, for males and mean systemic exposure (AUC 0-24hr) and C max values, 
were 2940  (hr*ng/mL) and 528  (ng/mL), respectively, for females.  
Upon evaluation of the injection site photographs, no irritation was observed but transient 
redness was noted.  Upon microscopic evaluation at 24 hours and 14 days, test article r elated 
findings in the injected subcutaneous tissue was noted.  These findings were characterized by 
necrosis of the subcutaneous fat and muscle accompanied by acute inflammation at 24  hours 
post-dose.  At 14 days, residual necrotic tissue in the injected areas was noted with evidence of 
on-going healing characterized by chronic inflammation and fibrosis.  There was no evidence of 
systemic toxicity at 24 hours or 14 days 
The 14 day interim results of this study demonstrated that administration of 5.68 to 7.14  mg/kg 
to males and 5.32 to 6.33 mg/kg to females of RZL -012 (test article) over 20  injection sites in the 
pig was associated with expected changes in subcutaneous fat  temperatures, transient changes in 
neutrophils, and marked localized irritation and tissue necrosis.  The increase in subcutaneous fat 
temperature was considered to be related to the mechanism of action of RZL 012, and an 
indication of the efficacy of the  test article.  The microscopic changes noted at 24 hours were 
beginning to resolve at 14 days.  The results of the final time point at 84 days will allow for 
assessment of the resolution of these findings.  
1.2.3.  Additional Nonclinical Studies  
• Secondary pharmac ology (searching for off -target receptors).  
• Establishing pharmacokinetic (PK) parameters and investigation of RZL -012 
metabolism by liver enzymes and half maximal inhibitory concentration (IC 50) in 
cell-culture.  
• Testing RZL -012 mutagenicity, utilizing th e Ames test.  
• Pyrogenicity in rabbits.  
• Assessment of RZL -012 binding  to the β3 receptor in cellular and nuclear receptor 
functional assays.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    28 CONFIDENTIAL  • Assessment of RZL -012 uptake by the 5 -HT neurotransmitter in the absence and 
presence of a 5 -HT2B agonist.  
• Assessmen t RZL -012 effect on 5 -HT neurotransmitter uptake and release in cellular 
and nuclear receptor functional assays.  
• ADME -Toxicology  
• Genotoxicity  
Methods and results from these safety studies are described in the Investigator's Brochure.  
1.2.4.  Clinical Studies  
Razie l Therapeuti cs has conducted an Exploratory  phase 0 , randomized, double -blind, vehicle -
controlled study aimed at the evaluation of safety and thermogenesis -induction of three 
escalating doses of RZL -012 drug product in overweight  and obese  volunteers .  In each cohort , 
8 subjects  were enrolled , 6 active and 2 control .  Study design is presented in the following table:  
Table 1:  Phase 0 Clinical Trial Design  
 Cohort 1  Cohort 2  Cohort 3  
Number of Subjects – Active/Placebo  6/2 6/2 6/2 
Total Dose RZL -012 (mg)  5 10 20 
Dose per NOAEL*  1/50th  1/25th  1/12.5th  
Number of Injections  1 2 4 
 
Primary objective :  Evaluation of the overall safety of RZL -012 subcutaneous injection and the 
existence of a thermogenic effect.  
Secondary objective :  Determination of RZL -012 pharmacodynamics  and pharmacokinetics .  
Evaluation of the extent, duration and tissue associated changes of the thermogenic response to 
RZL -012, via minimal invasive means including injecte d-site thermogenesis imaging, MRI , and 
punch biopsy following injection into the subcutaneous fat. 
Primary Endpoints:  
Safety - The primary safety endpoint was no more than two subjects experiencing a dose-limiting 
toxicity ( DLT ) event.  
Efficacy - The primary efficacy endpoint was a significant thermogenesis at the injected site 
compared with the contra -lateral, non -injec ted site.  This was monitored by sensitive (± 0.1 °C) 
infra-red thermal camera.  A thermogenic effect was defined by an increase of 1  °C in the 
injected site when compared to the surroundings and/or the contra -lateral (non -injected site), 
apparent at least  28 days after injection and non -related to inflammatory response as determined 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    29 CONFIDENTIAL  by inflammatory cytokines.  The primary efficacy evaluation was supported by results from 
secondary endpoints, including MRI, biopsy , and biomarkers.  
Secondary Efficacy Endpoin ts: 
1. The k ey secondary efficacy endpoint wa s the duration of the thermogenic effect in those 
subjects demonstrating clear thermogenesis by 28 days after injection.  
2. Local reduction in fat mass as determined by MRI.  
3. Clinical laboratory changes, incl uding improvement in fasting blood glucose and lipid 
profile.  
4. Anthropometric changes, including body weight change.  
5. Establishing pharmacokinetic profile for RZL -012 
6. Elucidation of the histological changes account for the thermogenic effect by biopsy of the 
injection site.  
7. Exploration of mode of action by evaluation of inflammatory markers and cytokines  
Results:  
This was a dose escalation exploratory clinical trial of RZL -012, a first -in-class, new chemical 
entity.  
RZL -012 was generally foun d to be safe in all cohorts .  There were no clinically significant 
changes in vital signs, ECG and almost all blood laboratory tests .  Most adverse events ( AEs) 
associated with RZL -012 injection occurred confined to the injection site and were transient .  
Biopsy from the injected site revealed no damage to the skin 56 days following RZL -012 
injection .  The only significant local AE was an abscess in one subject in the lower abdomen on 
the injected side , but at a considerable distance  from the  site of inject ion. 
In another patient , a severe elevation of alanine aminotransferase ( ALT ) blood levels and a 
moderate elevation of AST blood levels were seen 14 days following injection .  This elevation 
was transient (resolved within 14  days).  In light of the pre -clinical findings (increased AST 
blood levels in female rats sacrificed on Day 2  following RZL -012 injection) and in light of the 
findings in this clinical trial, Raziel therefore plans to monitor closely (on 24hr, Day 3, Day 7, 
Day 14, Day 21, Day 28 and will follow further if necessary) liver functions in the next clinical 
trial.  There were no other systemic clinically significant AEs.  
The exploration of thermogenesis induction by RZL -012 in humans was successful.  A raise in 
temperature at the injection site was mostly evident in cohort 3 (the highest dose) at Day 14 or 
Day 21 foll owing injection in RZL -012 treated subjects only .  This change in temperature was 
captured and recorded by the infra -red camera.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    30 CONFIDENTIAL  Although not statistical ly significant, a drop in the change from baseline in SFM ratio 
(treated/control) over time by MRI in RZL -012 treated subject of cohort 3 was evident in 5 of 
6 treated subject s.  The drop in subcutaneous fat associated with a drop in weight (more than 
1 kg) and Body Mass Index ( BMI ) when compared to baseline and is evident in 4 of 6 RZL -012 
treated subject s of cohort 3 on Day 28 and/or Day 56, while controls gained weight and 
increased BMI.  
Biopsy did not yield enough tissue (because punch biopsy did not penetrate deep enough to reach 
the remodeled tissue) , and therefore , it was not possible to demonstrate  that thermogenesis is due 
to adipose tissue remodeling.  
Although not statistical significant, a decrease in TC and FFA blood levels was evident in 
subjects of the RZL -012 treated group in cohort 3 .  This may imply to the mode of action of 
RZL -012 as stimu lation of a thermogenic tissue such as BAT, is known to cause a systemic 
effect via the mobilization of glucose and FFA from the blood stream to feed the ongoing local 
thermogenesis .  Thus, lipolysis of WAT triacylglycerols (TAG) stores is accelerated and the 
uptake of F FA derived from blood -born lipoproteins is increased due to the action of lipoprotein 
lipase (LPL).  Raziel assumes that circulating FFA utilization by the RZL -012-induced 
thermogenic tissue resulted in lower levels of FFA in the blood, a pr ocess that may be beneficial 
for health .  There was no consistent pattern to suggest a connection between inflammation 
markers and cytokines levels and changes in thermogenic activity reflecting the intended effect 
of the drug as opposed to local inflammat ion and distinguish between events related to M1 and 
M2 macrophages .  Though, an increase in Adiponectin blood level was evident at Day 21 and 
Day 28 in 3 of 6 subjects treated with RZL -012, but not in controls .  Adiponectin was found to 
be an obligatory m ediator of cold -induced browning of WAT (9).  Adiponectin can be elevated 
under various conditions, including those that trigger tissue remodeling in favor of 
thermogenesis such as chronic cold exposure .  Although we do not know what triggered 
elevation of adiponectin in this study , it is kn own that downstream effects of adiponectin can 
promote the type of tissue remodeling we are expecting.  
Raziel concludes that the potential risk -benefit balance for RZL -012 is favorable, and that it is 
likely that higher doses of RZL -012 will generate better results .  This will be assessed in the next 
clinical trial . 
Method s and results of  this exploratory study are described in the IB. 
2. PURPOSE AND STUDY OBJECTIVES  
2.1. PURPOSE  
An open label, phase 2a clinical trial for the evaluation of safety and efficacy of RZL -012 for the 
treatment of women with lipedema involving substantial fat above the knee or women and men 
with nodular Dercum's disease . 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    31 CONFIDENTIAL  2.2. STUDY OBJECTIVES  
2.2.1.  Primary  
The primary objective is the evaluation of the overall safety of RZL -012 following  injection into 
the subcutaneous fat in patients with lipedema.  
2.2.2.  Secondary  
The secondary objective is the evaluation of local fat reduction, its extent, duration and tissue 
associated changes  and the extent of pain relief , in response to RZL -012 treatment, utilizing 
minimal invasive means (ultrasound) following subcutaneous injection of RZL -012 into fatty 
tissue below the skin.  
3. STUDY DESIGN  
3.1. DESCRIPTION OF STUDY DESIGN  
This is  an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above 
the knee or women  and men  with nodular Dercum's disease.  Each cohort will have 6 subjects 
who will receive RZL -012. 
3.2. DOSE RATIONALE  
The initial dose was determined by the NOAEL established by the Good Laboratory Practice 
(GLP ) extended single dose toxicology study and by the previous phase 0 clinical trial in wh ich 
20mg RZL -012 was the highest dose achieved.  This initial study is an escalating dose study.  If 
no more than 1 subject experiences intolerable side effects within 14 days following the injection 
of the last dosed group, according to schedule, an addit ional cohort of volunteers will be 
administrated the next dose level.  
Cohort 1 - will be comprised of subjects with Dercum's disease.  All subjects will be injected with 
RZL -012. Dosing will be calculated according to the size of the nodule (diameter) as det ermined 
by ultrasound: 5mg/cm2 reaching a maximal dose of  40 mg RZL -012 per subject  (1/6.25 the 
NOAEL based on the Human Dose Equivalent [HED]  GLP Toxicology studies).  
Cohort 2 - will be comprised of subjects with lipedema with substantial fat above the kn ee and 
will be conducted in a dose escalation manner.  
The first 3 subjects will receive 60mg RZL -012 (1/ 4.688th the NOAEL based on HED from GLP 
toxicology study).                                                                                      
The last 3 subjects will receive 80mg RZL -012 (1/3.125th the NOAEL based on HED from GLP 
toxicology study).                                                                                                                                                                                                                                                                        
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    32 CONFIDENTIAL  3.3. DOSING  
3.3.1.  Dosing Regimen  
The dosing regimen will be a  single dose treatment injection  of RZL -012 in multiple sites.  
Six subjects in cohort 1, al l assigned to the RZL -012 treatment group will be dosed at a maximal 
dose of 40 mg RZL -012 (approximately 1/ 6.25th the NOAEL as determined in the G LP 
toxicology study) . Dosing will be calculated according to the size of the nodule (diameter) as 
determined by ultrasou nd in a dose of  5mg/cm2: 
Nodule of  2-2.9cm diameter, as determined by ultrasound, will be injected 2  injections (0.1 mL 
each, 1 cm apart) ; total of 10  mg RZL -012.  
Nodules of 3-3.9cm diameter, as determined by ultrasound, will be inje cted 3  injections (0.1 mL 
each, 1 cm apart) ; total of 15  mg RZL -012.  
Nodules of 4-8cm diameter, as determined by ultrasound, will be injected 4  injections (0.1 mL 
each, 1 cm apart) ; total  of 20  mg RZL -012. 
Cohort 1  – Dercum's disease  
Number of Subjects – Active  6 
Nodule size – diameter (cm)  2-2.9 3-3.9 4-8 
Total Dose of RZL -012 (mg)  10 15 20 
Dose per NOAEL*  1/25th 1/18.75th 1/12.5th 
Number of Injections  2 3 4 
 
Six subjects in cohort 2, all assigned to the RZL -012 treatment group , will be dosed as follows:  
The first 3 subjects will receive 30mg RZL -012 in 6 injections (0.1mL each)  in one leg followed 
by 30mg RZL -012 ( 6 injections, 0.1mL each) in the second leg adding up to 12 injections of 
60mg RZL -012 (1/ 4.688th the NOAEL based on HED from GLP toxicology study).  
The last 3 subjects will receive 40mg RZL -012 in 8 injections (0.1mL each) in one leg followed 
by 40mg RZL -012 (8 injections, 0.1mL each) in the second leg adding up to 16 injections of 
80mg RZL -012 (1/3 .125th the NOAEL based on HED from GLP toxicology study).  
*based on HED from GLP toxicology  
 
 
 Cohort 2  - Lipedema  
Number of Subjects – Active  2 2 
Total Dose RZL -012 (mg)  60 80 
Dose per NOAEL*  1/4.688  1/3.125  
Number of Injections  12 16 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    33 CONFIDENTIAL   
Dosing of subjects in each cohort will progress consecutively from one individual to the other at 
7-day intervals . This study design will allow the physicians to  monitor safety for at least 7 days 
prior to dosing the next subject.  For cohort 2 the decision to proceed to the next dose level will 
be made after reviewing all safety data collected by Day 14 within 2 ± 1d o f the last dosed 
subject. The trial will proceed within a cohort provided that no more than one subject 
experiences intolerable side effects in a cohort, and based on the decision made by the Principal 
Investigator ( PI) and the Medical Monitor .   
3.3.2.  Intolerab le Side Effect  
An intolerable side effect defined as any of the following treatment -related adverse drug 
reactions (ADRs):  
Any Grade 3 or greater event except for the foll owing (For the following event s, a discussi on 
will be held by the PI and the Medical Monitor  to decide whether considered as an intolerable 
side effects):  
o Flu-like symptoms and fever that responds to standard treatment within  72 hours  
o Localized edema and erythema  
o Pruritus  
o Pain 
o Skin/soft tissue infl ammation  
o Fat Atrophy  
o Liver enzymes abnormality  
o Non-significant lab abnormalities, lasting less than 7 days   
 
To establish a threshold for clinical abnormalities and liver enzyme abnormalities the following 
tables were formed  for main expected side effects . For the following abnormalities,  associated 
with the injection site or treatment  intolerable side effect would be any Grade 3  or greater event : 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    34 CONFIDENTIAL  Clinical Abnormalities  Table  
* Erythema – the measured local reaction at the greatest single diameter beyond the injected area surface of all 
injections ( For Dercum's disease – nodules of 2 -2.9 cm diameter 2*2 cm, nodules of 3 -3.9 cm diameter 3*2 cm 
nodules of 4 -8 cm diameter 4*2 cm . For lipedema -12*2 cm for the first subjects , 15*2cm for the following subjects  
and 16*2cm for the last subjects ), the measurement should be recorded as a continuous variable.  
**Induration –– the measured local reaction at the greatest single diameter beyond the injected area surface of all 
injections ( For Dercum's disease – nodules of 2 -2.9 cm diameter 2*2 cm, nodules of 3 -3.9 cm diameter 3*2 cm 
nodules of 4 -8 cm diameter 4*2 cm. For lipedema -12*2 cm for the first subjects, 15*2cm for the following subjects 
and 16*2cm for the last subjects ), the measurement should be recorded as a continuous variable.  
Liver Enzyme Abnormalities  Table  
 
Study discontinuation is to be considered by the investigator in any case of  an intolerable side 
effect and the actions taken are to be fully documented in source documents and Case Report 
Forms (CRFs).  Local Reaction to 
Injectable Product  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life 
Threatening 
(Grade 4)  
Pain  Does not interfere 
with activity 
Repeated use of non -
narcotic pain reliever 
> 24 hours  Interferes with 
activity  Any use of narcotic 
pain reliever beyond 
7 days following 
injection or prevents 
daily activity  Emergency room 
(ER) visit or 
hospitalization  
Tenderness   Discomfort to touch 
or with movement  Significant 
discomfort at 
rest Prevents daily 
activity  ER visit or 
hospitalization  
Erythema/Redness *  2.5 - 7 cm  7.1 - 15 cm  > 15 cm  Necrosis or 
exfoliative 
dermatitis  
Induration/Swelling* *  2.5 - 7 cm and does 
not interfere with 
activity  7.1 - 15 cm or 
interferes with 
activity  >15 cm or prevents 
daily activity  Necrosis  
Serum *  Mild  
(Grade 1)  Moderate  
(Grade 2)  Severe  
(Grade 3)  Potentially Life 
Threatening  
(Grade 4)  
Liver Function Tests –ALT, AST 
increase by factor  3 x ULN  3 – 5 x ULN  5-10 x ULN  
beyond 10 days  > 10 x ULN  
beyond 10 days  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    35 CONFIDENTIAL  To be considered an intolerable side effect, such an event must be considered to be possibly or 
probably related to the study drug . 
Subjects experiencing an intoler able side effect will be withdrawn from the study, but followed 
for toxicity.  
The study may also be prematurely terminated in any of the following cases:  
• Recurring serious or severe ADR clinically evaluated by PI  as warranting study 
termination.  
• A decisi on made by Sponsor and/or IRBEC and/or local regulatory agency to terminate 
the study.  
 
4. STUDY ENDPOINTS  
4.1. PRIMARY ENDPOINTS  
The primary endpoint will be the e valuation of the overall safety of RZL -012 injection i nto the 
subcutaneous fat in Derc um's disease and lipedema.  The trial will proceed within a cohort 
provided that no more than one subject experiences intolerable side effects in a cohort .  
4.2. SECONDARY ENDPOINTS  
Following are the study's secondary endpoints:  
1. For lipedema subjects - The redu ction in loca l subcutaneous fat in the injection site 
region  as compared to baseline as assessed by  leg circumference above the knee 
assessments , see definition in Section  6.1.16.2.1  and by the reduction in nodules size 
and/or numbers assessed by ultrasound, see definition in Section 6.1.14.2.2. 
2. For Dercum's disease subjects - The reduction in local subcutaneou s fat in the injection 
site region as compared to baseline assessed by the reduction in nodules size and/or 
numbers  by ultrasound , see definition in Section 6.1.14.2.2 . 
3. Extended duration of the fat reduction effect.  To that end, ultrasound images and 
circumfere nce measurement will be followed for 56 days , see definition in Section 
Error! Refere nce source not found. . 
4. Elucidation of the tissue changes by ultrasound of the injection site to include reduction 
in fat thickness and nodular quality , see definition in Section 6.1.16.2.4 . 
5. Improvement in loc al pain as measured by Comparative Pain Scale and by the reduction 
in the use of analgesics , see definition in Section 6.1.16.2.4 . 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    36 CONFIDENTIAL  6. Improvement in QOL and function in lipedema subjects as measured by questionnaire 
(such as The Lower Extremity Functional Scale (LEFS)),  see definition in 
Section  6.1.16.2.5 . 
5. STUDY POPULATION  
5.1. INCLUSION CRITERIA  
Subjects meeting all of the following criteria will be eligible for study participation : 
1. Post-menopausal (at least 2 years) women no more than 65 years ol d, with lipedema 
involving substantial fat above the knee or nodular Dercum's disease in such women and 
in men 20  - 65 years with nodular Dercum's disease.  
 
2. For Dercum's disease subjects – at least 2 nodules to be injected of at least 2cm diameter  
each, as determined by ultrasound  
3. For lipedema subjects - Significant subcutaneous fat above the knee as determined by 
circumference of 50cm  
4. Generally considered h ealthy according to medical history, physical examination, ECG 
and laboratory evaluation with a special emphasis on metabolic parameters (fasting 
glucose concentration < 200 mg, normal blood pressure).  
5. Subjects must be able to adhere to the visit schedule and protocol requirements and be 
available to complete the study.  
6. Subjects must sign an informed consent indicating that they are aware of the 
investigational nature of the study.  
5.2. EXCLUSION CRITERIA  
Subjects meeting any of the following criteria will be ex cluded:  
1. Unable to tolerate subcutaneous injection.  
2. Subjects with uncontrolled cardiac, hepatic, renal or neurologic/psychiatric disorders, that 
in the opinion of the investigator , put the subject at significant risk, are not eligible.  
3. Positive blood screen for Hepatitis B surface antigen (HbSAg), Hepatitis C virus (HCV), 
or Human immunodeficiency virus (HIV), or positive urine screen for alcohol or drugs of 
abuse (unless prescribe d by a physician).  
4. Subjects with a clinical history of primary or secondary immunodeficiency, autoimmune 
disease or subjects taking immunosuppressive drugs such as corticosteroids are ineligible.  
5. As a result of medical review, physical examination, the PI  (or medically qualified 
nominee) considers the subject unfit for the study.  
6. Known sensitivity to components of the injection formulation.  
7. Prior wound, tattoo or infection in the treated area.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    37 CONFIDENTIAL  8. Prior invasive treatment such as surgery or injectable drug at  the RZL -012 injected area.  
5.3. SUBJECT IDENTIFICATION  
A unique code numbers will be assigned by the investigator to the trial subject rather than the 
subjects’ names, personal identification numbers, and/or addresses to protect the subject's 
identity.  The co de numbers and initials will be used in lieu of the subject's name when the 
investigator reports AEs and/or other trial related data.  
5.4. REMOVAL, REPLACEMENT OR EARLY WITHDRAWAL OF SUBJECTS 
FROM ASSESSMENT  NOT DUE TO INTOLERABLE SIDE EFFECTS  
Subjects experiencing a n intolerable side effect  will be withdrawn from the study, but followed 
until the event resolves or becomes stable. I f only one subject is withdrawn or removed from the 
study, and no more than on e subject experience  intolerable side effects , then the subject will not 
be replaced .   
6. STUDY PROCEDURES AND ASSESSMENT  
6.1. DEFINITIONS OF STUDY PROCEDURES  
6.1.1.  Informed Consent  
Prior to initiation of any study procedures, each subject will undergo an Informed Cons ent 
process in which the subject voluntarily confirms their willingness to participate in the trial, after 
having been informed of all aspects of the trial relevant to their decision to participate.  The 
investigator, or a person designated by the investig ator, will fully inform the subject of all 
pertinent aspects of the trial.  In addition, the investigator, or a person designated by the 
investigator, will inform the subject that he is free to refuse to enter the study or to withdraw 
from the study at any  time, for any reason.  
The Informed Consent Form (ICF) approved by the IRB/EC will contain a description of the 
study’s purpose, procedures, inconveniences and potential risks, and anticipated benefits.  
Prior to a subject’s participation in the trial, an ICF will be signed and personally dated by the 
subject and by the person who conducted the Informed Consent discussion.  
If a subject is unable to read, he may not participate in the study.  
Prior to participation in the trial, the subject will receive a copy of the signed and da ted written 
ICF.  During participation in the trial, the subject will receive a copy of the signed and dated 
consent form updates and a copy of any amendments to the written information provided to 
subjects.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    38 CONFIDENTIAL  The investigator should document in the source data that the Informed Consent was signed prior 
to subject's participation in the study and according to the International Conference on 
Harmonization Good Clinical Practice ( ICH-GCP)  guidelines, as described above.  
6.1.2.  Medical History  
Subjects' medical histor y should be ful ly documented at Screening Day  (14 through 2 days prior 
to baseline), to ensure compliance with study inclusion criteria and the absence of circumstance 
mentioned in the exclusion criteria.  Medical history information must include, but not be limited 
to, past and present medical conditions, concomitant non -drug treatments and hypersensitivity to 
drugs.  
6.1.3.  Concomitant Medication  
All concomitant medication given 1 month  prior to study entry,  including blood and blood 
products,  dietary supplements, and non -prescription drugs will be listed at screening/baseline.  
Each entry will include the treatment's start date, treatment name (Generic), reason for use, 
dosing regimen (dose and frequency of use), route of administration, and stop date (if 
applicable).  The clinical significance of the medication use will be decided by the investigator.  
Study subjects will be routinely questioned for changes in the administration of concomitant 
medication dur ing the trial  and changes should be updated from medical records as well .  
6.1.4.  Physical Examination  
The investigator (or medically qualified nominee) will conduct a complete physica l examination , 
height and weight measurements  at Screening Day  (performed 14 through 2 days prior to 
baseline).  Clinically significant abnormal findings except overweight and obesity should be 
discussed with the Sponsor.  
Additional physical examination to assess subject's safety and weight measurement will be 
performed on study visi t on Day 28.  
6.1.5.  Pain  Measurement   
Local pain as measured by Comparative Pain Scale (Appendix II) will be measured at Screening 
Day (performed 14 through 2 days prior to baseline) in order to establish a baseline to compare 
following drug injection. For lipede ma subjects Comparative Pain Scale  will be measured for 
each leg and for Dercum's disease subjects for each selected lipoma for injection.  
Additional pain measurements wi ll be performed on study visits Day 14, 28 , and 56.   
Pain will be also assessed by Subject's self -recording the daily use of analgesics  in a diary . 
Subjects will receive a diary on Screening Day and will start recording daily painkiller use  along 
the trial  till Day 28 . A week before Day 56 visit, subjects will record their da ily use of 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    39 CONFIDENTIAL  analgesics . Diaries will be checked routinely on each study visit and data will be captured in the 
CRFs.  
6.1.6.  Quality of Life and Function Measurement  
QOL  and function assessed by the LEFS questionnaire  (Appendix III)  will be measured in 
lipedema su bjects at Screening Day (performed 14 through 2 days prior to baseline) in order to 
establish a baseline to compare following drug injection.  
Additional pain measurements will be performed on study visits Day 14, 28 and 56.  
6.1.7.  Vital Signs Measurements  
Subjec ts' vital signs wi ll be measured at Screening Day  (performed 14 through 2 days prior to 
baseline) in order to ensure compliance with study inclusion criteria.  
Vital signs measurements will include systolic and diastolic sitting position blood pressure, pu lse 
rate, respiratory rate, and body oral temperature.  
Additional vital signs measurements to assess subject's safety will be performed at baseline visit 
(Day 0) prior to drug injection, 2h ± 30min following drug injection, the following day (Day 1) 
after drug injection (24h ± 2h) and on study visits every 7 days thereafter, i.e., Day 7, Day 14 , 
etc. 
Additional pulse rate measurements to assess subject's safety will be performed at baseline visit 
(Day 0) prior to drug in jection and 1h, 2h, 4h, 8h,  24h following injection in the opposite hand of 
blood sampling.  
6.1.8.  Serology Assays  
Assays for HCV, HbSAg,  and HIV will be conducted at Screening Day 1 (performed 14 through 
2 days prior to baseline) in order to ensure compliance with study inclusion criteria.  
6.1.9.  Clinical Laboratory Tests  
Clinical laboratory tests will be conducted at Screening Day (performed 14 through 2 days prior 
to baseline) in order to ensure compliance with study inclusion criteria.  Additional studies will 
be conducted on different  study visits according to schedule as written below.  The maximum 
total blood volume will be 30 mL per visit.  Every out -of-range value will be assessed by a 
physician and deemed as either clinically significant or clinically not significant . Values that 
represent a change from baseline in subject’s medical status according to the laboratory normal 
ranges will be adequately documented as an AE  as described in Section 9. 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    40 CONFIDENTIAL  6.1.9.1.  Hematology  
Hematol ogy tests will be conducted at Screening Day  (performed 14 through 2  days prior to 
baseline) in order to ensure compliance with study inclusion criteria.  Additi onal Hematology 
testing will be conducted to assess subject's safety on baseline v isit prior to injections, at  24hr ± 
2h following injection and  on study visit Day  3, 7, 14 and 28 . 
Hematology tests will include Complete blood count (CBC) (including White blood cells [WBC] 
differential values) and coa gulation tests: White blood cells (WBC), Red b lood cells ( RBC ), 
Hemoglobin, Hematocrit, Mean corpuscular volume (MCV), Mean corpuscular hemoglobin 
(MCH), Mean corpuscular hemoglobin concentration (MCHC), R ed cell distribution width  
(RDW), Platelets, Mean p latelet volume (MPV), Fibrinogen, International normalized ratio  
(INR), Partial thromboplastin time (PTT)  and Prothrombin time (PT) . 
6.1.9.2.  Serum Chemistry Analysis  
Testing of blood chemist ry values will be conducted at Screening Day  (performed 14 through 2 
days prior to baseline) in order to ensure compliance with study inclusion criteria.   
Additional Serum Chemistry testing will be conducted at Day 0 (before injection), 24hr ± 2hr 
following injection and on study visit Day 3, 7, 14 and 28 . 
Serum chemistry will include:  Sodium, Calcium, Potassium, Phosphorus, Glucose, Liver 
enzymes (AST, ALT, Lactate dehydrogenase  [LDH], Creatine -kinase MM [ CK-MM] , Gamma -
glutamyltransferase  [GTTP ], Alkaline phosphatase [ALP]), Bilirubin, Creatinine, BUN, Tot al 
protein, Albumin, Amylase , Creatine phosphokinase [CPK ], C-reactive protein [CRP]).  
In case of CK -MM >x5 ULN, subjects will undergo clinical assessment for symptoms and 
alternative causes, and renal function will be assessed (including urinalysis).  
6.1.9.3.  Urin e Drug Screen  
Urine drug screen will be conducted at Screening Day (performed 14 through 2 days prior to 
baseline) in order to ensure compliance with study exclusion criteria .   
Drugs of abuse will include: amphetamines, barbiturates, benzodiazepines, cannabinoids, 
cocaine, alcohol, opiates, phencyclidine and propoxyphene.  
6.1.9.4.  Urinalysis  
Urinalysis will be conducted at Screening Day (performed 14 through 2 days prior to baseline) in 
order to ensure compliance with study inclusion criteria and to allow differential diagnosis in 
case of urinary tract associated AE.  Additional urinalysis testing will be conducted on study visit 
Day 14 and 28.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    41 CONFIDENTIAL  Urinalysis will include: Nitrite, Sodium, Potassium, Calcium, Phosphate, Protein, Red blood 
cells ( RBC ), WBC, Blood, Glucose, Ketone bodies, Bilirubin, Urobilirubin, Urine specific 
gravity, Osmolality , and pH.  
6.1.10.  ECG  
Subjects' ECG will be performed at Screening Day (performed 14 through 2 days prior to 
baseline) in order to ensure compliance with st udy inclusion criteria.  ECG is to be performed on 
at least a triplicate of heartbeats for all measurements and will be recorded at a speed of 25 
mm/sec.  Additional ECGs will be performed at 4h ± 30min, 8h ± 30min and 24h  ± 2h following 
drug injection (Da y 0-1) and on Days 14  and 28.  
Computerized ECG analysis will include:  Heart rate, Rhythm, PR interval, QRS axis, and QRS 
duration.  The corrected QT interval and QTc will be calculated manually according to the 
Frederica  formula.  ECG will be recorded at a standard speed of 25 mm/sec and standard 
amplitude of 10  mm/mV.  
6.1.11.  Draize Score  
Subjects' skin irritancy will b e evaluated by Draize score at Screening Day (performed 14 
through 2 days prior to baseline) in order to establish a baseline to compare following drug 
injection. For lipedema subjects evaluation of Draize score will be  performed for each leg and 
for Dercum's disease subjects for each selected lipoma for injection.  
Addition al skin irritancy evaluation to assess subject's safety will be performed at baseline visi t 
prior to injection, and on 2h  ± 30min following inje ction, on the following day 24h ± 2h  after 
drug injection and on study visits Day 7, 14, 21, 28 and 56 .   
Skin i rritancy observations in the injected sites and contra -lateral sites will be scored using the 
Draize scale for scoring skin reaction:  
Erythema and eschar formation  Edema formation  
No erythema  0 No edema  0 
Very slight erythema (barely perceptible)  1 Very slight edema (barely perceptible)  1 
Well defined erythema  2 Slight edema (edges are well defined by 
definite raising)  2 
Moderate to severe erythema  3 Moderate edema (raised approximately 1mm)  3 
Severe erythema (beet redness) to slight 
eschar formation (injuries in depth)  4 Severe edema (raised more than 1mm 
extending beyond area of exposure)  4 
6.1.12.  Photography of the Injected Site  
Documentation of the skin condition and fat reduction eff ect in the injected area will be 
conducted at S creening Day (performed 14 through 2 days prior to baseline).  Additional 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    42 CONFIDENTIAL  photography will be performed at Day 1 (24h  ± 2h following drug injection) and on study visits  
Day 7, 14, 21, 28 and 56.  
Photography with a digital camera will include : 
1. For Dercum's disease – Each of the injected site  
a. A picture from above  
b. A side picture  
For each lipoma, the distance away from the lipoma with  the best view of the skin will be 
recorded  and fixed throughout  the study to assess lipoma size changes.  
2. For lipedema  
a. Both sites above the knees  
b. Sites of each knee separately  
c. A side picture of each knee  
Photography with a digital camera will be performed according to a detailed written manual.  
 
6.1.13.  Leg Circumference  
Leg circumfere nce measurement will be conducted at Screening (performed 14 through 2 days 
prior to baseline) to ensure compliance with study inclusion criteria and at Day 0 (before 
injection)  to establish  a baseline.  Additional  leg circumference measurement s will be performed 
on Day 28 and 56.  
The subject will be instructed to remove all garments from the legs and stand upright  barefoot.  
The technician wi ll stand on the subject’s side and will palpate the knee area to locate the 
suprapatellar fat . If there is  no excess to the suprapatellar fat  measure 4-6 cm from the knee.  
With a cosmetic pencil,  draw a horizontal line  and record  its distance from the floor.  Extend the 
measuring tape around the leg. Position the tape in a horizontal plane at the level of the 
measurement mark.  Check that the tape sits parallel to the floor and lies snug but does not 
compress the skin.  Always position the zero end of the tape below the section containing the 
measurement value.  Take the measurement in centimeters to the nearest  0.1 cm  (one digit after 
the decimal point).  The technician will take three measurements of leg circumference. When the 
measurement is measured  the same twice (±0.5cm),  that measurement  will be  used. If 
measurement are taken and all three are different, a  fourth measurement will be taken  until the 
same measurement is  achieved twice.  
6.1.14.  Imaging: Ultrasound (US)  
Evaluation of Ultrasound ( Vevo 2100 or 3100 with transducers at 20, 50 or 70 mHz ; or Esaote  
MyLab  Gamma Ultrasound System  with 20 mHz transducer ) will be conducted at Screening 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    43 CONFIDENTIAL  (performed 14 through 2 days prior to baseline) to ensure compliance  with study inclusion 
criteria and establishing a baseline . For Dercum's disease subjects  - nodule size and quality  will 
be assessed , for lipedema subjects – nodular size (if applicable), nodular quality and fat thickness 
will be assessed .  Additional U S will be performed on Day 28 and 56 . 
Nodular quality for Dercum's subjects will be assessed according to the following parameters:  
capsule visibility, h yperechoic or hypoechoic tissue , reverse starry sky (small black dots all over 
consistent with angiolipoma) , flurry or snowstorm appearance, l ocation measured to the skin  and 
vascularity internal or around the lipoma . 
Nodular  quality for lipedema subject s will be assessed according to the following parameters:  
hyperechoic or hyperechoic  tissue, f lurry or snowstorm , internal hypoechoic round ed area 
consistent with a vessel and d istance from skin . 
Additional ultrasound imaging will be conducted at Day 0 (before injection):  
- For Dercum's disease subjects - nodule size evaluation to ensure proper dose injection.  
The selected nodules for injection will be marked in circles with a non -erasable pen.  This 
mark should be strengthened on every visit.   
Assessment of nodular size will be by diameter (mm) and surface (mm2) in three dimensions as 
illustrated below:  
- Height  
- Width  
- Length  
-  
- For lip edema subjects – assessment of presence of nodules to be injected  along the 
horizontal plane 4-6 cm in the suprapatellar fat . The selected nodules for injection will be 
marked in circles with a non -erasable pen.  This mark should be strengthened o n every 
visit.  If no nodules are noted in the horizontal plane, dru g will be in jected in to the fatty 
tissue and in this case small nodules seen in ultrasou nd will be followed for changes . 

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    44 CONFIDENTIAL  6.1.15.  Adverse Events  
The information obtained during weekly subjects questioning, review of subject’s compliance 
record, physical examinatio ns, vital signs measurements, blood testing, and by any other means 
will be evaluated in light of baseline medical data and thus provide the basis for adverse events 
identification and grading.  
The trial will proceed within a cohort and from one cohort to  the next as long as no more than 
one subject experiences intolerable side effects and base d on the decision made by the PI .  
Proceeding from one subject  to the next will be based on the decision made after reviewing all 
safety data collected by Day 7 within 2 ± 1d of the last dosed subject in each cohort . 
The AEs reported during the trial will be graded ( see Section 9), documented , and assessed in 
light of their clinical significance and relation to investigational product.  In addition, the 
following information regarding the AE must be obtained: AE descr iption, start date, end date (if 
applicable) or ongoing, severity, seriousne ss, relationship to study drug,  outcome (e.g. , resolved / 
unresolved), and action taken (e.g. , concomitant medication).  The sponsor or the sponsor 
representative will provide info rmation regarding serious adverse event ( SAE ) expectedness 
based on data included in the IB .  AE monitoring will be conducted throughout subject’s 
participation up to 56 days after injection.   
6.1.16.  Evaluation of Response  
Evaluation of response will be conducted on Day 7 and every 7 days thereafter till Day 28.  
6.1.16.1.  Evaluation of Primary Endpoints  
6.1.16.1.1.  Safety and Tolerability Monitoring  
For determination of the study's primary end point, evaluation of safety and tolerability will be 
conducted according to definiti ons and guidelines below.  
Safety and tolerability will be assessed by the study medical staff (e.g. , PI, site coordinator, and 
study nurse) and the study subjects on the basis of the following:  
1. AEs and SAEs, including severity, relation to study treatment and classification by 
whether or not these events comprise intolerable side effects . 
2. Physical exams, Draize score and vital signs measurements.  
3. Urine testing.  
4. Blood laboratory testing for change s in hematology and chemistry values.  
5. ECG  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    45 CONFIDENTIAL  6. Subjects questioning - full medical history during screening, routine AE reporting , 
tolerability monitoring  and through review of subject’s analgesics  use diary . 
6.1.16.2.  Evaluation of Secondary Endpoints  
6.1.16.2.1.  Local Fat Reductio n for Lipedema Subjects  
For lipedema subjects, local reduction in fat mass will be evaluated by measurement of the 
circumference of the leg above the knee.  A local fat reduction is defined as a reduction 
(compared to baseline) in the circumference of the  leg above the knee . 
6.1.16.2.2.  Local Fat Reduction   
Local fat reduction in all subjects will be evaluated by ultrasound .  Local fat reduction is defined 
as the reduction in nodules size and/or numbers  in the injected area as compared to baseline. 
Ultrasound  will be evaluated in  all subjects  at baseline  and at Day 28 . 
6.1.16.2.3.  Duration of the fat reduction effect  
The duration of the local fat reduction in all subjects will be evaluated by ultrasound and by leg 
circumference above the knee in lipedema subject s at Day 56 compared to baseline and to Day 
28. 
6.1.16.2.4.  Tissue  Changes  
Tissue  changes will  be evaluated by ultrasound.  Tissue changes are define d as changes in fat 
thickness and nodular quality at Day 28 and Day 56 as compared to baseline . 
6.1.16.2.5.  Improvement in Local P ain 
Improvement in local pain will be assessed by Comparative Pain Scale and by reduction in the 
use of analgesics  (dose and/or times a day) by Day 28 and Day 56 with comparing to baseline.   
6.1.16.2.6.   Improvement in Quality of Life  and Function   
Improvement in QOL  and function in lipedema subjects as measured by questionnaire (such as 
LEFS)  by comparing to baseline at Day 28 and Day 56.  
6.1.16.3.  Compliance Monitoring  
Compliance monitoring will include the following procedures:  
• Compliance assessment by site coordinator at the study visit, including but not limited to 
subject questioning.  
• Completion of analgesics  use diary by the subject.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    46 CONFIDENTIAL  6.1.16.4.  Dispensing of RZL -012 Investiga tional Product  
The RZL -012 investigational product will be dispensed to the study site under monitored 
conditions by Nextar Ltd.  All procedures connected to investigational product's allocation (kits 
received at site, returned kits) will be properly docum ented, dated and signed in a designated site 
folder to allow full product tracking.  Source documents will be kept for the duration required by 
local regulation s and ICH -GCP (whichever is longer).  
6.1.16.5.  Questioning of Study Subjects  
Questioning of study subjects  during site visits and any unscheduled conversations (e.g. , by 
phone) with site staff will be fully documented in subject file.  Whenever possible, subject 
questioning should include, but not be limited to, inquiring information regarding occurrence and 
severity of AEs, treatment tolerability and compliance to future scheduled procedures and visits.  
6.2. STUDY VISITS  
Study visits will be fully doc umented in the CRF as described in Section 11.  Documentation 
will be completed in a timely manner and within 5 working days to ensure protocol adherence 
and comp liance with ICH -GCP.  
6.2.1.  Screening Procedures  
All information collected and documented during screening p rocedures will be reviewed to 
ensure eligibility in reference to study inclusion and exclusion criteria, and fully documented in 
subject  file. 
Screening visit should be performed  no later than 2 days prio r to baseline visit for all cohorts .  
Study S creening D ay procedures will include the following:  
• Informed Consent - Section 6.1.1  
• Medical History - Section 6.1.2  
• Concomi tant Medication - Section 6.1.3  
• Physical Examination - Sectio n 6.1.4  
• Pain Measurement – Section 6.1.5 
• QOL Measurement –Section 6.1.6 
• Vital Signs and Measurements - Section 6.1.5  
• Serology Assays – Section 6.1.8  
• Clinical Laboratory Tests - Section 6.1.9  
• ECG - Section 6.1.10  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    47 CONFIDENTIAL  • Draize Score – Section 6.1.11  
• Photography  of Injected Site  – Section 6.1.12  
• Leg Circumference – Section 6.1.12  
• Ultrasound – Section 6.1.12  
Subjects may be rescreened if they were screened and not dosed within 14 days .  The following  
procedures will be perfor med: Clinical Laboratory Tests (hematology, serum chemistry, and 
urinalysis), vital s igns,  Draize score and photography . 
6.2.2.  Study Randomization  
This is an open label study where all subjects will receive the investigational drug (RZL -012).  
6.2.3.  Study Treatment  
6.2.3.1.  Treatment with RZL -012 Investigational Therapy  
RZL -012 is an investigational product supplied as a single dose single treatment injection in 
multiple sites ( 2-16) of injections.  Before injection, subjects will be advised to keep their regular 
diet and physical activ ity. 
The injection dosing regimen and technique is crucial for the therapy safety and efficacy .  
Syringes w ill be filled with 0.1 mL RZL -012 and the number of syringes will be compatible with 
the number of injections.  All injections will be administered diagonally in 45  °, using a 1 mL 
Luer -lock syringe and a 30  G x 1/2" needle.  
The hole of the needle should be pointing into the fat layer  and the injection direction should be 
towards earth.   An attempt to pull the plunger should be made befor e injecting to ensure that no 
blood is coming out.  If so, the plunger should be pushed down to inject the medicine.  The 
formulation is viscose, therefore resistance is expected while injecting.  
For Dercum's disease  - The 1st cohort will be comprised of s ubjects with Dercum's disease. 
Subjects will receive a single treatment in multiple sites (2 -8) according to the design below  
Figure 2). 
 
 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    48 CONFIDENTIAL  Figure 1:  RZL -012 Injection Design in Dercum's Disease Subjects  
 
 
 
 
Injections will be diagonally (45 °) to the skin surface towards the center of the nodule and the 
distance between injections  in a nodule will be 1  cm (Figure 2). 
Figure 2:  RZL -012 Injection Sites  in Dercum's Disease Subjects  
 
 
 
 
 
For Lipedema  - The 2nd cohort will be comprised of subjects with lipedema with substantial fat 
above the knee . A grid line will be drawn with a makeup pencil in a horizontal plane  (Figure  3) 
4-6 cm from the suprapatellar fat and it s distance from the floor recorded . An attempt should be 
made to find palpable nodules along the grid line. The injection s ites will be marked  in circles 
with a non-erasable pen . This mark should be intensified  upon following visits.  Injections will be 
given in multiple sites (4 -8 in each leg) , diagonally (45 °) to palpable nodules , in the fat above 
the knee .  An attempt should be made to lift the nodule and inject into the middle of the fat -mass. 
If no nodules are noted in the horizon tal plane, drug will be injected into the fatty tissue (in this 
case small nodules seen in ultrasound will be followed for changes). Injections will be on the 
same horizontal plane.   
Figure 3:  RZL -012 Injection  in Lipedema   
 
 
 
 

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    49 CONFIDENTIAL  Injections will be spread as much as possible along the grid line and the distance between 
injected sites  (Figure 4) will be : 
• At least 3 cm - For subjects receiving 8 and 12 injections.  
• At least 2cm - For subjects receiving 16 injections.  
Figure 4:  RZL -012 Injection Sites  in Lipedema Subjects  
 
In lipedema subjects study will be performed in a dose escalation manner:   
The first 2 subjects will receive 20mg RZL -012 in 4 injections (0.1mL each) in one leg followed 
by 20mg RZL -012 (4 injections, 0.1mL each) in the second leg adding up to 8 injections of 
40mg RZL -012 (1/6.25th the NOAEL based on HED from GLP toxicology stud y).  
The next 2 subjects will receive 30mg RZL -012 in 6 injections (0.1mL each) in one leg followed 
by 30mg RZL -012 (6 injections, 0.1mL each) in the second leg adding up to 12 injections of 
60mg RZL -012 (1/4 .688th the NOAEL based on HED from GLP toxicology study).  
The last 2 subjects will receive 40mg RZL -012 in 8 injections (0.1mL each) in one leg followed 
by 40mg RZL -012 (8 injections, 0.1mL each) in the second leg adding up to 16 injections of 
80mg RZL -012 (1/3 .125th the NOAEL based on HED from GLP toxicology study).  
Within each cohort, dosing of the subjects will progress consecutively from one individual to the 
other with a minimum of 7 -days between subjects to assess safety. This study design will allow 
the physicians to  monitor safety for at least 7 days prior to dosing the next subject.  For cohort 2 
the decision to proceed to the next dose level will be made after reviewing all safety data 
collected by Day 14 within 2 ± 1d of the last dosed subject. The tr ial will proceed within a cohort 
provided that no more than one subject experiences intolerable side effects in a cohort, and based 
on the decision made by the PI and the Medical Monitor .   

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    50 CONFIDENTIAL  Each RZL -012 kit contains 1 vial (250  mg/5  mL) corresponding to th e number of subjects 
receiving treatment in each cohort.  
RZL -012 will be injected on baseline study visit.  
6.2.4.  Baseline Visit  
Baseline visit is defined in the study as Day 0 .  Baseline visit will be performed to complete 
screening evaluation, and to review  all procedures necessary to confirm subject eligibility.  
Subjects will stay under supervision in the study center till 8h + 3h following drug injection.  
Screening information may be considered for baseline data if acquired within the adequate 
timeframe as de scribed in  Table 2. 
Table 2:  Subject Information and Timeframes  
Information  Timeframe  Follow -up Timeframe  
Informed Consent Form  Signed prior to any study 
dedicated procedure   
Medical History and Concomitant 
Medications  At Screening  Day visit  
Physical examination  At Screening Day visit and at 
Day 28   
Pain Measurement  At Screening Day visit and at 
Days 14, 28  At Day 56  
QOL Measurement  in lipedema subjects  At Screening Day visit and at 
Days 14, 28  At Day 56  
Vital Signs  At Screening Day visit and at 
Days 0 (pre and following 
injection), 1, 7, 14, 21, 28   
Pulse rate  At Day 0 (following injection) 
and at Day 1  
ECG  At screening Day 1 visit, at 
Day 0  (following injection) 
and at Days 1, 14, 28   
Draize Score at the Injected Site  At Screening Day and at Days 
0 (pre - and following 
injection), 1, 7, 14, 21, 28  At Day 56  
Serology assays ( HbSAg , HCV and HIV)  At Screening Day  visit   
Drug screen  At Screening Day visit   
Serum chemistry  and Hematology  At Screening Day a nd at Day 
1, 3, 7, 14  and 28   
Urinalysis  At Screening Day visit and at 
Days 14 and 28  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    51 CONFIDENTIAL  Information  Timeframe  Follow -up Timeframe  
Ultrasound  for nodules quality and size. 
Fat thickness – for lipedema  At Screening Day visit and at 
Day 28  At Day 56  
Ultrasound  for nodules size and selection 
for injection  At Days 0 (pre - injection)   
Photography of the Injected Sites  At Screening Day visit and at  
Days 1, 7, 14, 21, 28  At Day 56  
AE Assessment  At Days 1, 3, 7, 14, 21, 28  At Day 56  
 
6.2.5.  Subject Site Visits  
Subject site visits will be performed ±  1 day from scheduled date . All data relevant for the visit 
needs to be obtained within 3 days (e.g. , blood tests) of visit.  
Subject sites visits will include procedures as described in Appen dix I. 
For site visit that results in study discontinuation, see termination visit in Section 6.2.6 . 
6.2.6.  Termination Visit  
Once study is di scontinued, all reasonable measures should be taken to perform a termination 
visit.  Termination visit should include all procedures necessary to complete subjects' records:  
AE reporting, any clinical laboratory test needed to evaluate unresolved AEs, eva luation of 
response, recovery of all clinical supplies and compliance diaries, and updating of subject 
contact information.  An effort should be made to perform all activities conducted on  visit Day 
28. 
6.2.7.  Unscheduled Visit  
Unscheduled visits will be performed  upon investigator's discretion, upon Sponsor request to 
redo tests with unusual results or complete missing results and may occur upon subject’s 
decision with no notification in advance.  Unscheduled visits will include any study procedure 
deemed necessar y, as described in Section 6.1. 
 
 
 
 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    52 CONFIDENTIAL  7. SAFETY CONSIDERATIONS AND GUIDANCE FOR INVESTIGATORS  
Adherence to protocol monitoring procedures along with the following safety guidance will aid 
and promote subject safety.  
7.1. STUDY RESTRICTIONS REGARDING CONCOMITANT MEDICATIONS  
Subjects may not receive the following medications while on study:  
• Chronic treatment with systemic steroids  or immunosuppressive drugs .  
• Chronic treatment with Non Steroid Anti -Inflammatory Drugs (NSAIDs) and  aspirin.  
• Any investigational product other than RZL -012.  
Before dosing, analgesic gels such as Lidocaine (e.g., Emla) or Pramoxine should be used to 
numb the injected site .  An ice pack may be applied on the site of injection following dosing to 
help re duce pain.  At day 1 following injection application of the anti-histamine Benadryl  Gel 
(Diphenhydramine hydrochloride 1 % for topical use only ) should be initiated  prophylactically, 
according to drug instructions for use , to avoid  itching at the injected area .  Benadryl Gel should 
be applied  for 7 days.  
Use of nattokinase is prohibited and the use of other supplements or complementary 
medicines/botanicals  should be approved by the PI , except for conventional multivitamin 
supplements.  The use of prohibited supplements should be stopped a week before injection.  
7.2. SAFETY MEASUREMENTS  
Simple measures may help avoid specific AEs associated with the use of the RZL -012 
investigational product .  Thus, study subjects must be  informed of possible AEs that occurred in 
animal studies (rats and pigs) : 
• Any injection site reaction may occur.  Pain, swelling, itching, edema, erythema, 
hematoma , etc. 
• Slight transient injection site bleeding following injection may occur.  
• Itching in t he injected area may occur, and study subjects should be advised to use an 
antihistamine gel for topical use according to drug recommendations, wear wide cotton 
shirts, prevent touch with irritable clothing, avoid scratching and avoid exposure to direct 
sun.  Itching is expected till 7 days following drug injection.  
• Local erythema in the injected area.  
• Local heat in the injection area.  
• Study restrictions regarding concomitant medications are listed in Section 7.1.  
• The local subcutaneous fat reduction may  appear as a slight dip in the skin surface.  This 
decline may be temporary and transient.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    53 CONFIDENTIAL  • Transient increase  (72%)  in the WBC  count  by 24  hours following injection , which 
returned to basal level after 14 days .  Probably associated with the inflammatory response 
at the site of injection  and involve neutrophils , monocytes  and eosinophil s.  
• Increased level of BUN  and of creatinine  and minimal single cell necrosis was observed 
in tubular epithelium at cortico medullary junction of kidney in rats receiving a dose 25 
times the highest dose in this study .  All abnormalities were found to be  reversible by 
Day 14.  
• Increased  AST level  which is most typical of myofiber injury associated with study 
related procedures .  This elevation was found to be reversible by Day 14.  
• Transient increase of serum CRP levels (in rats) which returned to the basic level  by 
14 days.  
• Marked irrita ncy in the injected subcutaneous tissue resulting in coagulation necrosis of 
relatively large areas in the subcutaneous tissue planes acutely.  Necrosis persisted for up 
to 14 days and was accompanied by early evidence of healing in the form of chronic 
inflammation and fibrosis.  
• Local inflammation (minimal to moderate) with muscle degeneration,  epidermal/dermal 
necrosis (minimal to severe) and parakeratosis (minimal) .  Inflammation observed at 
injection site was also extended to adjacent subcutaneous adipose tissue  (SAT) .  By 56 
days the inflammation was minimal , muscle degeneration  was not evident and 
inflammation to adjacent  SAT  was present.  
• A slight elevation in body temperatures was noted in male pigs.  
• Sinus tachycardia (in pigs),  occurring at the 4 hour interval post dosing. 
• In addition, other acceptable treatment to relieve drug -related AE's should be used at 
Investigator's discretion.  
Study subjects must be informed of possible AEs that occurred in clinical studies (phase 0):  
• At the  injection site -local and transient: erythema, edema , pruritus, anesthesia , pain, 
mass ( subcutaneous scar ). 
• Abdominal abscess  
• Transient moderate to severe elevation of the liver enzymes: ALT and AST.  
7.3. PREMATURE DISCONTINUATION FROM STUDY  
Study will be prematurely discontinued in any of the following cases:  
• Subject's request.  
• Any life -threatening (i.e. , Grade 4) AE may cause prematurely discontinuation.  
• Systemic hypersensitivity reaction may cause premature discontinuation.  
• Any G rade 3 or 4 ADR (defined in Section 9.3) clinically evaluated by the PI  and/or 
Sponsor as warranting subject discontinuation.  
• Non-compliance: Subject's non -compliance with study proced ures as evaluated by PI 
and/or S ponsor as warranting subject discontinuation.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    54 CONFIDENTIAL  • Other reasons regarded by PI as warranting subject 's discontinuation.  
• Premature study termination as described in Section 7.4.   
Subjects who discontinue the study prematurely will be queried whether an AE contributed t o 
their decision.  
7.4. PREMATURE STUDY TERMINATION  
The study will be prematurely terminated in any of the following cases:  
• Recurring serious or severe ADR (defined in Section 9.1) clinically evaluated by PI 
and/or S ponsor as warranting study termination.  
• A dec ision made by S ponsor and/or IRB/EC and/or local regulatory agency to terminate 
the study.  
7.5. DEVIATION FROM STUDY PROTOCOL  
The investigator shall not deviate from the study protocol without first obtaini ng a written 
approval from the S ponsor, or its official designee, and  if applicable, from the local IRB/EC 
according to local regulations.  
In the event of medical emergencies, the investigator shall use appropriate medical judgment and 
will remove the subject from any imm ediate hazard, then notify the S ponsor or its offici al 
designee and if applicable, the local IRB/EC, within 2 days, of the type of emergency and course 
of action taken.  
Any other changes to or deviations from the protocol will be made as an amendment to the 
protocol and must be approved by t he Sponsor or i ts official designee and the local IRB/EC 
before they can be implemented.   Accordingly, the S ponsor will not assume responsibility or 
liability for any unauthorized deviation from or change to the protocol.  
8. INVESTIGATIONAL PRODUCT AND VEHICLE SPECIFICATION S 
8.1. DESCRIPTION OF RZL -012 
RZL -012 investigational drug is intended for a single dose in multiple injections into the 
subcutaneous fat.  The injection dosing regimen and technique is crucial for the therapy safety 
and efficacy . 
8.2. FORMULATION, PACKAGING AND LABELING  
The RZL -012 drug is a ready to use liquid to be injected to the subcutaneous fat, supplied in a 
1 vial kit.  1 vial contains 250 mg/5 mL RZL -012 in formulation F12. 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    55 CONFIDENTIAL  8.3. STORAGE AND STABILITY OF RZL -012 AND VEHICLE  
The RZL -012 kit will be stored in the site pharmacy at monitored room temperature conditions 
(22 ± 7 ᵒC) protected from light.  Storage space will be separate, designated and adequately 
labeled as containing investigational product.  
Stability program of RZL -012 is ongoi ng and sit e inventory will be managed by the S ponsor 
according to accumulating stability data.  Suitability of the product's expiration date must take 
into consideration and comply with FIFO (First In First Out) principals.  
The storage conditions are summa rized in Table 3. 
Table 3:  RZL -012 Storage Conditions  
Storage Conditions  Maximal Storage Duration  
Individual vials:  
Room te mperature (15 -30 ᵒC) According to expiration date as will be 
provided by manufacturer.  
* Stability program for RZL -012 is ongoing and site inventory will be managed by the 
Sponsor according to accumulating stability data.  
 
8.4. DOSAGE, DISPENSING AND ADMINISTRATION OF RZL -012 AND VEHICLE  
8.4.1.  Dosage  
RZL -012 therapy is available in vials of 250  mg/5m L. 
8.4.2.  Administration and Instructions for Use  
Each individual vial must be kept and handled at room temperature.  
The vial should be manually shaken before consumpt ion.  
1 mL Luer -lock syringes with RZL -012 solution should be filled with 30  G 1/2" sterile needle as 
described below:  
• Cohort 1 - Dercum's disease subjects :  
Nodule of  2-2.9cm diameter -will be injected 2 * 0.1 mL/syringe/nodule  
Nodules of 3-3.9cm diameter - will be injected 3 * 0.1 mL/syringe/ nodule  
Nodules of 4-8cm diameter - will be injected 4 * 0.1 mL/syringe/ nodule  
In total -A maximum of 8* 0.1 mL/syringe/subject.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    56 CONFIDENTIAL  • Cohort 2  - lipedema subjects :  
First 3 subject s: 6*0.1 mL/syringe/leg, a total of 12* 0.1 mL /syringe/subject . 
Last 3 subjects: 8*0.1 mL/syringe/leg, a total of 16* 0.1 mL/syringe/subject.  
One vial may be used for dosing of one subject. Breached vials will not be re -used for other 
subjects .  Each vial must  be placed back into the container.  All open vials must be kept until  the 
end of the study  for the Sponsor to decide either to discard or return to the Sponsor . 
8.5. ACCOUNTABILITY OF RZL -012 AND VEHICLE  
The RZL -012 investigational product was manufactured by PharmaCore (USA) and complies 
with cGMP requirements.  Formulation and packing was done by Nextar (Israel) and complies 
with cGMP requirements.  
The RZL -012 investigational product and vehicle will be supplied in kits, in quantities as needed 
to comply with  the treatment of site subjects according to the study protocol.  
Site coordinator will notify the Sponsor or its official designee, in a timely manner and no less 
than 14 working days in advance, of any supply requirements to prevent shortage.  
Shipment, st orage and inventory documentation will be updated regularly and kept in the 
investigation files at the site to allow inspection and trace of the supplied product.  
9. ADVERSE EVENTS  
9.1. ADVERSE EVENT DEFINITIONS  
9.1.1.  Definition of AE 
An AE is defined as any untoward m edical occurrence in a clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abn ormal laboratory finding, for example), symptom, or disease temporally 
associated with the use of a medicinal product, whether or not considered related to the 
medicinal product.  This definition includes any abnormalities or anomalies that were not seen a t 
baseline or which worsened during the course of the study, if present at baseline.  
9.1.2.  Definition of Serious Adverse Event  
A SAE is defined as any AE occurring at any dose that results in any of the following outcomes:  
• death  
• a life -threatening AE, as defined below  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    57 CONFIDENTIAL  • subject hospitalization or prolongation of existing hospitalization  
• a persistent or significant disability/incapacity  
• a congenital anomaly/birth defect  
• important medical event, as defined below  
A life -threatenin g AE is any AE that places the subject, in the view of the investigator, at 
immediate risk of death from the reaction as it occurred (i.e., it does not include a reaction that, 
had it occurred in a more severe form, might have caused death).  
An important medical event is an AE that may not result in death, be life -threatening, or require 
hospitalization but may be considered a serious AE when, based upon appropriate medical 
judgment, may jeopardize the subject and may require medical or surgical interventi on to prevent 
one of the outcomes listed above.  It can also include AEs otherwise judged to be serious by 
either the investigator or the Sponsor.  
9.1.3.  Definition of Adverse Drug Reaction  
AEs associated with the use of investigational product (i.e., probably or  possibly related to 
treatment as defined in Section 9.3) are also termed ADRs.  
9.2. ADVERSE EVENT GRADING  
AE will be documented and graded according to the National Cancer Institute  Common 
Terminology Criteria for Adverse Events (CTCAE) v4.03 June 14, 2010) (10).  
AE that do not appear in the CTCAE will be graded as follows:  
• Mild (Grade 1):  Sign or symptom, usually transient, requiring no special treatment and 
generally not interfering with usual activities.  
• Moderate (Grade 2):  Sign or symptom, which may be ameliorated by simple therapeutic 
measures, may interfere with usua l activity.  
• Severe (Grade 3):  Sign or symptom that is intense or debilitating and that interferes with 
usual activities and/or requires hospitalization.  Recovery is usually aided by therapeutic 
measures and the discontinuation of the study product may b e required.  
• Life-threatening or disabling (Grade 4):  Sign or symptom that is life-threatening or 
disabling.  
• Death (Grade 5):  Death related to AE  
9.3. CAUSALITY ASSESSMENT OF ADVERSE EVENTS   
All AEs will be evaluated by the investigator and assigned an estim ated relationship to the 
RZL -012 investigational product.  The terms "probable", "possible", "unlikely", or "unrelated" 
refer to the association with the use of the investigational product, as defined  below in Table 4.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    58 CONFIDENTIAL  Medical judgment should be used to determine the relationship, considering all relevant factors, 
including pattern of reaction, temporal relationship, confounding factors such as c oncomit ant 
medication, concomitant diseases and relevant history.  
Assessment of causal relationship should be recorded directly in subjects ’ CRF.  
Definition of AEs causality is specified in the table below ( Table 4). 
Table 4:  Definition of Causality  
TERM  DEFINITION  CLARIFICATION  
Unrelated  This category applies to those AEs 
which , after careful consideration, 
are clearly due to extraneous 
causes (disease, environment, etc.)   
Unlikely 
Related  In general, this category can be 
considered applicable to those 
AEs, which after careful medical 
consideration at the time they are 
evaluated, are judged to be 
unrelated to the study procedures/ 
investigational product.  An AE may be considered unlikely related if or when (must 
have two):  
▪ It does not follow a reasonable temporal sequence from the 
study procedures/administration of the investigational 
product.  
▪ It could readily have bee n produced by the subject’s clinical 
state, environmental or toxic factors, or other modes of 
therapy administered to the subject.  
▪ It does not follow a known pattern of response to the study 
procedures/investigational product.  
Possibly 
Related  This categ ory applies to those AEs 
for which, after careful medical 
consideration at the time they are 
evaluated, a connection with the 
study procedures/investigational 
product administration appears 
unlikely but cannot be ruled out 
with certainty.  An AE may be cons idered possibly related if or when (at least 
two of the following):  
▪ It follows a reasonable temporal sequence from study 
procedures/administration of the investigational product.  
▪ A causal relationship to the experimental treatment cannot 
necessarily be r easonably excluded and an alternative 
explanation (e.g., concomitant investigational product or 
concomitant disease) cannot be reasonably suggested as 
causing the treatment emergent AE .  
▪ It follows a known pattern of response to the study 
procedures/ investigational product.  
Probably 
Related  This category applies to those AEs 
which, after careful medical 
consideration at the time they are 
evaluated, are felt with a high 
degree of certainty to be related to 
the study 
procedures/investigati onal 
product.  An AE may be considered probably related if or when (at least 
three of the following):  
▪ It follows a reasonable temporal sequence from study 
procedures/administration of the investigational product.  
▪ It could not be reasonably explained by th e known 
characteristics of the subject’s clinical state, environmental 
or toxic factors, or other modes of therapy administered to 
the subject.  
▪ It disappears or decreases on cessation or reduction in dose .  
There are important exceptions when an adverse e vent does 
not disappear upon discontinuation of the investigational 
product, yet investigational product -relatedness clearly 
exists.  
▪ It follows a known pattern of response to the study 
procedures/investigational product.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    59 CONFIDENTIAL  TERM  DEFINITION  CLARIFICATION  
Definitely 
Related  This category applies to those AEs 
which, after careful medical 
consideration at the time they are 
evaluated, are felt with definite 
certainty to be related to the study 
procedures/investigational 
product.  An AE may be considered definitely related if or when all of the  
following apply:  
▪ It follows a reasonable temporal sequence from study 
procedures/administration of the investigational product.  
▪ It could not be reasonably explained by the known 
characteristics of the subject’s clinical state, environmental 
or toxic fac tors, or other modes of therapy administered to 
the subject.  
▪ It disappears or decreases on cessation or reduction in dose .  
There are important exceptions when an adverse event does 
not disappear upon discontinuation of the investigational 
product, yet investigational product -relatedness clearly 
exists.  
▪ It follows a known pattern of response to the study 
procedures/investigati onal product.  
*In this protocol,  Unlikely is deemed as Unrelated.   
9.4. UNEXPECTEDNESS OF ADVERSE DRUG REACTIONS  
An ADR is considered unexpected when its nature or severity is not consistent with the 
applicable product information (i.e., RZL -012 Investigator's Brochure).  
9.5. ADVERSE EVENT  REPORTING  AND MONITORING REQUIREMENTS  
9.5.1.  General  
All AEs, serious and non -serious, will be fully documented in both source documents and CRFs 
as described in Section 6.1.13 , and each AE will be assessed in light of its clinical significance.   
For each AE, the investigator will provide the onset, end, intensity, treatment required, outcome, 
seriousness and action t aken with the investigational drug.  The investigator will determine the 
relationship to the investigational drug, i.e., causality assessment, for each AE.  
Any AE occurring prior to initiation of first dose, after initiation of the first dose and or durin g 
any point throughout the study should be recorded on the AE page of the CRF.  All AEs 
occurring until subject is terminated from the study (28 days after the injection of RZL -012 and 
in the highest dose cohort until 6 months from injection of RZL -012), s hould be captured in the 
CRF.  AEs should be recorded in the CRF using the medical terminology found in the source 
documentation.  Whenever possible, diagnoses should be given when signs and symptoms are 
due to a common etiology.  
Occurrence of any Grade 4 and Grade 3 or 4 ADR must warrant clinical evaluation by the 
treating investigator and reported to the Sponsor within 7 calendar days.  
ADRs graded >  1 will be followed -up until resolution, or for a maximal duration of 6 months 
after RZL -012 injection, whi chever occurs first.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    60 CONFIDENTIAL  9.5.2.  SAE Reporting  
The PI or his designee must report to the Sponsor any SAE occurring after injection of the study 
treatment, regardless of their relationship to the investigational product.  
Sponsor contact details for SAE reporting:  
Racheli Gueta , Rachel.gueta @raziel -therapy.com, fax: 972 -2-625-0901 . 
An initial report must be f axed or emailed to rachel.gueta @raziel -therapy.com, fax: 972 -2-625-
0901 within 24 hours of becoming aware of the event and must include SAE general description, 
start date, end date (if a pplicable), the reason for evaluation as a SAE, basic subject information, 
assessment of the relationship to the investigational product, expectedness, and study therapy 
information.  
Follow -up information, including outcome and treatment , shall be faxed o r emailed within 
48 hours.  Source d ocuments to support the SAE (e. g., discharge summary, test results) shall be 
included in the report.  
A complete SAE report must be sent to the Sponsor at the first possible date and no later than 
7 calendar days after S AE end date.  In addition to the information described in the initial report, 
this report will include CTCAE  description and grading, treatment given (if applicable), SAE 
outcome, an assessment of the relationship to the investigational product, and expect edness.  
SAE will be recorded on designated CRF forms in a timely manner and no later than 7 calendar 
days after its end date.  
The PI or his designee will submit the SAE report to IRB/EC according to applicable local 
regulations and will update the Sponso r. 
9.5.3.  Expedited Reporting  
Expedited reporting by PI to IRB/EC is warranted for all Suspected Unexpected Serious Adverse 
Reactions (SUSAR), i.e., unexpected SAEs that are considered related to study product as 
defined in Sections 9.1.2 , 9.1.3 , and 9.4).  Additional cases will be communicated by PI to 
IRB/EC via expedited reporting when required by local regulation.  
Expedited reports will be submitted to the applicable regulatory authorities  by the Sponsor or 
designee within the required timelines according to local regulations.  
Any pregnancy of a subject and of a partner of a study male subject after dosing is considered an 
immediate reportable event.  
Such events must be reported within one (1) working day of the investigator becoming aware of 
the event.  Pregnancies shall be followed for the duration of the pregnancy.  It is the PI’s 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    61 CONFIDENTIAL  responsibility to provide to the Sponsor follow -up information on the  outcome of the pregnancy 
including information about any sequelae.  
10. STATISTICAL CONSIDERATIONS  
10.1. STUDY DESIGN AND OBJECTIVE  
This is an open label, 2 cohort, clinical trial in women with lipedema with substantial fat above 
the knee or women and men with nodul ar Dercum's disease. Each cohort will have 6 subjects 
who will receive RZL -012. 
• The 1st cohort will be comprised of subjects with Dercum's disease  
• The 2nd cohort will be comprised of subjects with lipedema with substantial fat above the 
knee.  
Primary  objective:  Evaluation of the overall safety of RZL -012 following injection into the 
subcutaneous fat in patients with lipedema.  
Secondary objective:  Evaluation of local fat reduction, its extent, duration and tissue associated 
changes, in response to R ZL-012 treatment, utilizing minimal invasive means (ultrasound) 
following subcutaneous injection of RZL -012 into fatty tissue below the skin.  
10.2. STUDY ENDPOINTS  
10.2.1.  Primary Safety Endpoints  
The primary safety endpoint is the incidence of intolerable side effects  and AEs. 
10.2.2.  Secondary Efficacy Endpoints  
Secondary efficacy endpoints include:  
• For lipedema subjects - The reduction in local subcutaneous fat in the injection site 
region as compared to baseline based on ultrasound (reduction in nodules size and/or 
numbers) and leg circumference above the knee assessments.  
• For Dercum's disease subjects - The reduction in l ocal subcutaneous fat in the injection 
site region as compared to baseline based on ultrasound ( reduction in nodules size and/or 
numbers ).  
• Extended duration of the fat reduction effect.  To that end, ultrasound images and above 
the knee circumference meas urement will be followed for 56 days . 
• Elucidation of the tissue changes by ultrasound of the injection site to include reduction 
in fat thickness and nodular quality . 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    62 CONFIDENTIAL  • Improvement in local pain as measured by Comparative Pain Scale and by the reduction 
in the use of analgesics . 
• Improvement in QOL  and function in lipedema subjects as measured by questionnaire 
(such as LEFS).  
10.2.3.  Safety and Tolerability Endpoints  
Safety endpoints  include : 
• Incidence of AEs and SAEs, by severity  and relation to study treatment.  AEs will be 
coded using MedDRA version 19.1 (or higher) .  
• Physical examination (including Draize score)  
• Vital signs  
• Blood laboratory tests  
• ECG  
10.3. SAMPLE SIZE JUSTIFICATION  
This study is planned following a 6 subject s per group paradigm . A maximum of 12 evaluable 
subjects will be included in the study ( 6 subjects with  Dercum's disease and 6 subjects with 
lipedema ) and followed for as long as 2 months . 
10.4. ANALYSIS SETS  
10.4.1.  Safety Analysis Set  (SA)  
The SA will consist of all enrolled subjects who received the study treatment , (exposed 
population), including subjects prematurely withdrawn.  
All enrolled subjects receiving at least one study drug injection are consid ered evaluable for the 
SA set.  
10.4.2.  Efficacy Analysis Set (EF)  
The EF will consist of all subjects from the SA analysis set without any  major protocol violations 
measured at baseline .  Subjects will be analyzed according to the treatment received.  
10.4.3.  Statistical Analysis of Analysis Sets  
The SA analysis set will serve as the p rincipal data analysis set for the analyses of the safety 
endpoints.  
The EF analysis set will serve as the principal data analysis set for the analyses of the efficacy 
endpoints.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    63 CONFIDENTIAL  10.5. STATISTICAL ANALYSIS  
10.5.1.  General  
Statistical analysis will be performed using SA S V9. 3 or higher (SAS Institute, Cary NC, USA).  
Statistical analyses will be mainly descriptive in nature where study data will be tabulated and 
summarized using the mean, standard deviation or standard error, median, minimum, maximum 
and number of subject s by cohort for continuous data.  For categorical data, results will be 
summarized via a count and percentage by cohort.  The results will be presented overall, per 
cohort and per cohort and dose. The effects of noncompliance, dropouts, and covariates, may be 
assessed to determine the impact on the general applicability of results from this study.  
If any statistical tests are performed, they will be two -sided.  The required significance level of 
findings will be equal to or lower than 5% .  Nominal p -values will be presented.  
Where confidence limits are appropriate, the confidence level will be 95%.  
10.5.2.  Subject Disposition  
A detailed description of subject accountability including count of  subjects included, exposed, 
completed (i.e. , subjects who c omplete the study treatment) and discontinued along with the 
main reason for discontinuation will be generated for each cohort and for all subjects.  All 
withdrawals from the study, taking place on or after study drug injection, will be fully 
documented in  the body of the Clinical Study Report.  
Note that the actual study duration is for a period of maximum 2 months , with efficacy analyses 
being conducted at 28 days  and 56 days . 
10.5.3.  Demographic and Baseline Characteristics  
Baseline will be defined as the last av ailable and evaluable parameter value before and closest to 
the injection .  If a rechecked value is used for baseline, it should be collected under the same 
conditions as for the planned ba seline . 
Baseline safety data will be presented along with subsequen t safety values assessed during or 
after dosing.  
10.5.4.  Primary Safety Endpoint  
The incidence of intolerable side effect s will be presented overall and by cohort along with two 
sided 95% exact binomial Confidence Interval (CI).  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    64 CONFIDENTIAL  10.5.5.  Efficacy Analysis  
Percent changes from baseline  in local fat reduction (circumference of the leg above the knee , 
nodules size and/or numbers in the injected area) and tissue changes  (fat thickness ), will be 
presented in tabular form by visit.  
Changes in nodular quality, local pain,  quality of life and function will be presen ted in tabular 
form by visit and cohort . 
10.5.6.  Safety and Tolerability  
Safety analyses will be descriptive in nature.  
All reported AEs will be coded to a standard set of terms us ing MedDRA coding dictionary  
(V19.1 or higher)  treatment .  
AEs and tolerability data will be presented descriptively by treatment and cohort .  AEs will be 
tabulated by body system, preferred term,  seriousness,  severity and relation to study drug by 
cohort.   Where applicable, changes in values over time (e.g. , lab values, vital signs, ECG s) will  
be presented ; this will include clinical laboratory evaluations (including CBC, blood chemistry 
and urinalysis), coagulation (INR, PTT and PT ), cytokines, vital signs, and ECGs .  Shift tables of 
normal / abnormal versus baseline may be presented as well.   
Draize scores will be presented in tabular format by visit , treatment, and cohort.  
10.6. HANDLING OF MISSING DATA  
No imputation of missing data wil l be performed.  
10.7. INTERIM ANALYSIS  
No interim analysis is planned.  
 
11. DATA COLLECTION, STUDY MONITORING, AND DA TA DISCLOSURE  
11.1. DATA COLLECTION AND REPORTING  
Each study subject will be assigned an individual CRF  that will contain all of the relevant study 
informa tion.  The investigator shall ensure that all data is completely and accurately recorded on 
the CRF s throughout trial duration.  
Data reported on the CRF  that are derived from source documents should be consistent with the 
source documents or the discrepan cies should be explained.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    65 CONFIDENTIAL  All fields and blanks in the CRF s will be completed.  The following abbreviations are to be used 
when values or answers are not available: NA  = Not applicable, ND  = Not done, UNK  = 
Unknown, CONT  = Continued.  
White -out or erasure  on the CRF is not permitted under any circumstances.  Any change or 
correction to a CRF should be dated, initialed, and explained (if necessary) and should not 
obscure the original entry (i.e. , an audit trail should be maintained).  If an entry on a CRF form is 
changed, the correction will be made as follows:   A single line will be drawn through the 
incorrect entry, the date and initials of the reporting individual will be added beside the entered 
change and/or correction, and an explanation will be a dded when applicable.  
When a subject withdraws from the study, regardless of cause, all final study evaluations should 
be attempted.  
If a subject is lost to follow -up, (i.e. , fails to return for scheduled visits) every reasonable effort 
must be made to c ontact the subject in order to determine why the subject failed to return.  All 
actions taken in this regard will be documented and dated in the CRF.  
Once completed, a copy of each completed CRF will be signed and dated by the investigator or a 
designated  represent ative and submitted to the S ponsor.  
11.2. RECORD KEEPING  
The investigator will maintain all records for this study including medical records, laboratory 
reports, ICFs , safety reports, subjects' CRF, and any other pertinent data.  All records are to be 
retained by the investigator for a period of fifteen years af ter completion of the study.  
11.3. SOURCE DATA AND SOURCE DOCUMENTS  
ICH-GCP defines source data as all information in original records and certified copies of 
original records of clinical findings, observations, or other activities in a clinical trial necessary 
for the reconstruction and evaluation of the trial.  Source data are contained in source documents 
(original records or certified copies).  
Source documents are defined as original documents, data, and records (e.g., hospital records, 
clinical and office c harts, laboratory notes, subject files, and records kept at departments 
involved in the clinical trial, etc.).  
The following data is to be recorded directly on the RZL -012 trial forms or CRF , which will be 
considered to be the source data:  
• Subjects' questioning,  e.g., pain, itching, topical antihistamine application.  
• Assessment of AEs relation to investigational product, i.e. , causality assessment, and 
expectedness reported by investigator.  
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    66 CONFIDENTIAL  The investigator should maintain the trial's essential documents  as required by ICH -GCP 
guidelines and the applicable regulatory requirements, and take measures to prevent accidental or 
premature destruction of these documents.  
Upon request of the monitor, auditor, IRB/EC, or regulatory authority, the investigator wil l 
ensure direct access to all requested trial -related records . 
11.4. STUDY MONITORING  
Monitoring procedures are required to assure compliance to ICH -GCP guidelines, the study 
protocol and local regulations.  
The investigator shall allow the S ponsor or its offici al designee to monitor and audit periodically, 
at mutually convenient times, all CRF and corresponding subject records .  The monitoring 
schedule will be based on Sponsor’s mo nitoring plan and  will be done by competent monitors 
per GCP by either Sponsor personnel or sponsor’s designee such as a Clinical Research 
Organization ( CRO ). 
11.5. CONFIDENTIALITY, DATA DISCLOSURE , AND PUBLICATION  
In order to protect subject confidentiality, a consecutive  ident ification number will be attributed 
to each subject enrolled to the trial.   In order to avoid identification errors, this number and 
subject’s initials (first letter of first name and the first letters of surname) will identify the subject 
and must be incl uded on all CRF s.  The investigator will complete subject identification on a 
confidential site log, which will be used for subjects' traceability and follow -up.  
Individual subject medical information obtained as a result of this study is to be considered  
confidential and disclosure to third parties other than the regulatory authorities, or other persons 
or organizations designated by the S ponsor, is prohibited.  Any medical information may be 
provided to the subject’s personal physician or to appropriate medical personnel responsible for 
the subject’s care.   Additionally, data generated from this study is to be provided, upon request, 
to the S ponsor’s monitors, as well as to the local IRB/EC.  Subject confidentiality is to be further 
assured by utilizing s ubject identification code numbers to identify subject data.  
All information supplied by Raziel Therapeutics Ltd. in connection with this study and not 
previously published, is considered confidential information.  This information includes, but is 
not li mited to, the IB, clinical protocol, CRF,  and other scientific data.  Any data collected during 
the study are also considered confidential.  This confidential information shall remain the sole 
property of Raziel Therapeutics Ltd, shall not be disclosed to others without the written consent 
of the Sponsor, and shall not be used except in the performance of this study.  The information 
developed during the conduct of this clinical study is also considered confidential, and will be 
used by the Sponsor in conne ction with the development of the product.  The information may be 
disclosed as deemed necessary by the Sponsor.  To allow the use of the information derived from 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    67 CONFIDENTIAL  this clinical study, the investigator is obliged to provide Raziel Therapeutics Ltd . with com plete 
test results and all data developed in this study.  
The S ponsor has full ownership of the original CRFs  completed as part of the study.  
By signing the clinical study protocol, the investigator agrees that the results of the study may be 
used for the purposes of national and international registration, publication, and information for 
medical and pharmaceutical professionals.  The authorities will be notified of the investigator's 
name, address, qualifications, and extent of involvement.  
The information obtained during this study may be made available to other investigators who are 
conducting similar studies.  
It is agreed that , consistent with scientific standards, publication of the results of the study shall 
be made only as part of a publication of the results obtained by all sites performing the protocol.  
Raziel Therapeutics Ltd. will disclose the results of the trial on th e basis of the final analysis and 
following the revision of a draft manuscript by the investigators, unless posting would 
compromise publication in a peer -reviewed medical journal or contravene national laws or 
regulations.   Study results may also be discl osed through presentations and abstract submissions 
at professional scientific meetings.  
12. HUMAN SUBJECTS  
12.1. DECLARATION OF HELSINKI  
Both the PI and the S ponsor will ensure that the study is conducted in agreement with the 
Declaration of Helsinki, ICH -GCP, and the local laws and regulation.  
12.2. INFORMED CONSENT  
As described in Section 6.1.1 . 
12.2.1.  LIABILITY AND INSURANCE CONDITIONS  
Raziel Therapeutics Ltd. holds a clinical trial liability insurance policy.  
A copy of the policy summary will be filled in the investigator's site file.  
 
 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    68 CONFIDENTIAL  13. REFERENCES  
1. Buck DW, Herbst KL. Lipedema: A Relatively Common Disease with Extremely Common 
Misconceptions. Plast  Reconstr Surg Glob Open. 2016;4(9):e1043.  
2. Herbst KL. Rare adipose disorders (RADs) masquerading as obesity. Acta Pharmacol Sin. 
2012;33(2):155 -72. 
3. Okhovat JP, Alavi A. Lipedema: A Review of the Literature. Int J Low Extrem Wounds. 
2015;14(3):262 -7. 
4. Suga H, Araki J, Aoi N, Kato H, Higashino T, Yoshimura K. Adipose tissue remodeling in 
lipedema: adipocyte death and concurrent regeneration. J Cutan Pathol. 2009;36(12):1293 -8. 
5. Warren Peled A, Kappos EA. Lipedema: diagnostic and management challenge s. Int J 
Womens Health. 2016;8:389 -95. 
6. Fonder MA, Loveless JW, Lazarus GS. Lipedema, a frequently unrecognized problem. J Am 
Acad Dermatol. 2007;57(2 Suppl):S1 -3. 
7. Forner -Cordero I, Szolnoky G, Forner -Cordero A, Kemény L. Lipedema: an overview of its 
clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome 
- systematic review. Clin Obes. 2012;2(3 -4):86 -95. 
8. Hansson E, Svensson H, Brorson H. Liposuction may reduce pain in Dercum's disease 
(adiposis dolorosa). P ain Med. 2011;12(6):942 -52. 
9. Hui X, Gu P, Zhang J, Nie T, Pan Y, Wu D, et al. Adiponectin Enhances Cold -Induced 
Browning of Subcutaneous Adipose Tissue via Promoting M2 Macrophage Proliferation. Cell 
metabolism. 2015;22(2):279 -90. 
10. NIH. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 2010 
[Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-
14_QuickRe ference_8.5x11.pdf . 
 
 
 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    69 CONFIDENTIAL  Appen dix I:  Trial Schedule of Events  
a. Study day is based on Day 0 defined as the day of RZL -012 injection.  Study Procedure  Screening Day  Baseline  
(Treatment)   Visit Schedule (Days 1 to 28)  Follow -up 
Study Daya Daya-(-14) 
through Day ( -2) Day a 0 Day 1  Day 3  Day 7  Day 14 Day 21  Day 28  Day 56  
Signed informed consent  X         
Medical history  X         
Concomitant Medication  X         
Complete physical exam  X       X  
Pain measurement  X     X  X X 
For lipedema subjects - QOL 
measurement  X     X  X X 
Serology assays (H bSAg , HCV, 
HIV)  X         
Urine Drug Screen  X         
Height and weight  X       X  
For Dercum's disease subjects – 
ultrasound assessing nodules size 
(diameter) and quality  X       X X 
For lipedema subjects – assessing 
fat thickness and nodular quality by 
ultrasound.  X       X X 
For lipedema subjects – 
measurement of leg circumference 
above the knee  X Pre c X      X X 
          
For lipedema su bjects – ultrasound 
assessing  nodules to be injected   Pre c X        
For Dercum's disease subjects – 
ultrasound re-assessing nodules size   Pre c X        
Photography of site of injection  X  X  X X X X X 
Serum Chemistry, Hematology b X Pre c X X X X X  X  
Urinalysis  X     X  X  
Draize score at the injected site d X Pre c X post c X  X X X X X 
Vital signs e X Pre c X post c X  X X X X  
Injection of RZL -012  X        
ECG f X X post c X   X  X  
Pulse rate g  X post c X       
Subjects diary recording of 
analgesics use  X X X X X X X X X 
AE assessment    X------------------------------------------------- ----------------------------------------- → 
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    70 CONFIDENTIAL  b. CBC, coagulation, serum chemistry analysis, renal and liver function,  urinalysis, CPK, amylase measurement: before 
injection,14d and 28d following injection  
c. Pre/post – refers to before/after injection respectively  
d. Draize score evaluation: before injection, 2h, 24h and 7d,  14d, 21d and 28d following injection  
e. Vital signs measurement: before injection, 2h, 24h and 7d,  14d, 21d and 28d following injection  
f. ECG is to be performed in triplicate for all measurements in given time point:  4h, 8h, 24h following injection  
g. Pulse rate measurements at given time points:  1h, 2h, 4h, 8h , 24h following injection in the opposite hand of blood sampling  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix II: Comparative Pain Scale   
Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    71 CONFIDENTIAL   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix III: Lower Extremity Functional Scale  
 
Activities  Extreme 
Difficulty or 
Unable to  
Perform Activity  Quite a Bit 
of 
Difficulty  Moderate  
Difficulty  A Little Bit 
of 
Difficulty  No 
Difficulty  
1 Any of your usual work, 
housework, or school 
activities.   0  1  2  3  4 
2 Your usual hobbies, re 
creational or sporting 
activities.   0  1  2  3  4 
3 Getting into or out of the 
bath.   0  1  2  3  4 
4 Walking between rooms.   0  1  2  3  4 

Raziel Therapeutics , Ltd.                                                                                      Protocol RZL -012-FD-P2aUS -001.7  
RZL -012  Version: 7 
 
26 July 2018    72 CONFIDENTIAL  5 Putting on your shoes or 
socks.   0  1  2  3  4 
6 Squatting.   0  1  2  3  4 
7 Lifting an object, like a bag 
of groceries from the floor.   0  1  2  3  4 
8 Performing light activities 
around your home.   0  1  2  3  4 
9 Performing heavy 
activities around your home.   0  1  2  3  4 
10 Getting into or out of a 
car.  0  1  2  3  4 
11 Walking 2 blocks.   0  1  2  3  4 
12 Walking a mile.   0  1  2  3  4 
13 Going up or down 10 
stairs (about 1 flight of 
stairs).   0  1  2  3  4 
14 Standing for 1 hour.   0  1  2  3  4 
15 Sitting for 1 hour.   0  1  2  3  4 
16 Running on even ground.   0  1  2  3  4 
17 Running on uneven 
ground.   0  1  2  3  4 
18 Making sharp turns while 
runni ng fast.   0  1  2  3  4 
19 Hopping.   0  1  2  3  4 
20 Rolling over in bed.   0  1  2  3  4 
 
Source: Binkley et al (1999): The Lower Extremity Functional Scale (LEFS): Scale 
development, measurement properties, and clinical application. Physical Therapy. 79:371 -383. 